Compounds for the treatment of neurodegenerative diseases

Cyclized 1H-benzo[d]imidazoles and heterocyclic isosteres address the issue of toxic metabolites in neurodegenerative disease treatments by enhancing cell viability and clearing subunit c accumulation, providing a safer and more effective therapeutic approach.

WO2026236424A1PCT designated stage Publication Date: 2026-11-12BOARD OF RGT UNIV OF NEBRASKA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027001
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for neurodegenerative diseases such as CLN3 disease are limited by the formation of toxic metabolites from Flupirtine and Retigabine, which cause hepatotoxicity and tissue discoloration, necessitating the development of neuroprotective compounds that avoid these toxic intermediates.

Method used

Development of cyclized 1H-benzo[d]imidazoles and heterocyclic isosteres that cannot form quinone diamine or azaquinone diimine toxicophores, activating autophagy and clearing subunit c of mitochondrial ATP synthase accumulation.

Benefits of technology

The compounds effectively protect cell viability and reduce toxic metabolite formation, demonstrating neuroprotective effects in CLN3 patient-derived iPSC models without inducing liver toxicity or tissue discoloration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027001_12112026_PF_FP_ABST
    Figure US2026027001_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are compounds and pharmaceutically acceptable salts thereof having the structure of Formula (I) or as disclosed in Table A herein, and methods of using the disclosed compounds to reduce or prevent accumulation of subunit c of mitochondrial ATP synthase (SCMAS) and in treating diseases or disorders associated with impaired autophagy. For example, the compounds of Formula (I) and Table A as disclosed herein are useful for methods of treating diseases and disorders including, without limitation, neurodegenerative diseases and disorders, including CLN3 disease, CLN6 disease, lysosomal storage disorders, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and other neurological conditions. Also provided are methods of synthesizing the compounds disclosed herein, and pharmaceutical compositions comprising the compounds disclosed herein.
Need to check novelty before this filing date? Find Prior Art

Description

Docket No. 31196 / 25102 / PCCOMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This is an International Application which claims priority to U. S. S. N. 63 / 801,255, filed May 7, 2025, the disclosure of which is incorporated herein by reference in its entirety.STATEMENT OF GOVERNMENT INTEREST

[0002] This invention was made with government support under W81XWH-22-1-0365 awarded by the Defense Health Agency, Medical Research and Development Branch, and T32 AG076407, and R01 HD106590 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND

[0003] The neuronal ceroid lipofuscinoses (NCLs), commonly referred to as Batten Disease, are a family of rare and fatal autosomal pediatric neurodegenerative disorders. These diseases are among the most common causes of dementia in the pediatric population. Individual NCLs are generally classified by the gene that is altered in the disorder, resulting in multiple subtypes. The most common subtype is CLN3 disease, in which there is a mutation in the CLN3 gene that encodes the CLN3 protein. The onset of CLN3 disease typically presents between 4-10 years of age with common symptoms including vision impairment and seizures. End-stage symptoms include blindness, spasms, and dementia, with poorly controlled seizures. Death eventually occurs in children with this disease during their teens or early twenties.

[0004] Common pathological hallmarks of CLN3 disease include lipofuscin accumulation in tissues and protein deposits in the brain, retina, and other areas. These storage materials are specifically located in the lysosomes. Additional hallmarks include impaired autophagy, accelerated apoptosis, and secondary inflammation. The accumulation of subunit c of mitochondrial ATP synthase (SOMAS) in lysosome-derived organelles has been observed in the NCLs. Treatment options such as gene therapy, stem cell therapy, and small molecule therapies have been explored as treatment strategies. However, due to the complex nature of the disease and an incomplete understanding of the functions of the disease-associated proteins, there is no disease-modifying therapy, with treatment limited to palliative care.

[0005] Analogues of Flupirtine, a non-opioid analgesic, and Retigabine, an anticonvulsant, have been shown to exhibit neuroprotective effects. However, the triaminoaryl moiety within the Flupirtine and Retigabine structures can be oxidized to reactive azaquinone diimine or quinone diimine metabolites, respectively, which can result in the formation of toxic hapten-protein adducts and tissue discoloration. Flupirtine-induced hepatotoxicity is linked to enzymatic oxidation processes that generate these reactive intermediates. Accordingly, there is a need for new therapeutic strategies that provide neuroprotective effects while avoiding the formation of such toxic metabolites.Docket No. 31196 / 25102 / PCSUMMARY

[0006] Provided herein are compounds, or pharmaceutically acceptable salts thereof, having the structure of Formula (I):whereinring A is a 5-membered heteroaryl moiety comprising 1 or 2 ring heteroatoms each independently selected from 0, N, and S;R1is H, halo, Ci-ehaloalkyl, -O-Ci-ehaloalkyl, or -S-Ci-ehaloalkyl;L is -Ci-3alkylene-O-, -Ci-salkylene-NR3-, -Ci-3alkylene-C(O)NH-, -Ci-3alkylene-NHC(O)NH-, -C(O)-, or -CH(OH)-;R2is H, -Ci-3alkyl, SH, -Ci-salkylene-OH, -NHC(O)O-Ci-3alkyl, -Co-aalkylene-Ce-ioaryl, -Co-3alkylene-(5-6 membered heteroaryl) wherein the heteroaryl comprises 1 or 2 heteroatoms each independently selected from 0, N, and S, or -Co-salkylene-O-Co-salkylene-Ce-ioaryl, and in each instance the aryl is substituted with 0, 1, or 2 substituents selected from halo and-O-Ci-shaloalkyl; andR3is H or -Co-salkylene-Ce-ioaryl, and the aryl is substituted with 1 substituent selected from halo and -Ci-3haloalkyl.

[0007] Also provided herein are compounds having a structure shown in Table A, or pharmaceutically acceptable salts thereof.

[0008] In some aspects, the present disclosure provides pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0009] In some aspects, the present disclosure provides methods of treating a neurodegenerative disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some cases, the disease or disorder may be CLN3 disease, CLN6 disease, a lysosomal storage disorder, Alzheimer's disease, Parkinson's disease, a neurodevelopmental disorder, traumatic brain injury, stroke, Amyotrophic Lateral Sclerosis, Huntington's disease, ischemia, attention deficit disorder, epilepsy, or other like diseases or disorders.

[0010] In some aspects, the present disclosure provides methods of reducing or preventing accumulation of subunit c of mitochondrial ATP synthase (SCMAS) in a cell, comprising contacting the cell with a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Docket No. 31196 / 25102 / PC

[0011] In some aspects, the present disclosure provides methods of treating a disease or disorder associated with impaired autophagy, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.BRIEF DESCRIPTION OF THE DRAWINGS

[0012] While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter, which is regarded as forming the present invention, it is believed that the invention will be better understood from the following description taken in conjunction with the accompanying drawings.

[0013] FIG. 1A shows phenotypic marker characterization at each stage of CLN3 patient-derived iPSC differentiation for NSCs. Scale bar (panel) = 10 pm.

[0014] FIG. 1B shows phenotypic marker characterization at each stage of CLN3 patient-derived iPSC differentiation for NPCs. Scale bar (panel) = 10 pm.

[0015] FIG. 1C shows phenotypic marker characterization at each stage of CLN3 patient-derived iPSC differentiation for neurons. Scale bar (panel) = 10 pm.

[0016] FIG. 2 shows a chart depicting CLN3-NPC cell viability determined from screening compounds of the disclosure. Values were determined after 24 hours at single 10 μM concentration in CLN3 Patient iPSC-derived NPCs. Statistics: One-way ANOVA. *, p <0.05, ***, p <0.001, ****, p < 0.0001. Values represent mean of at least three replicates ± SD.

[0017] FIG. 3A shows the dose-response curves of selected compounds 9a-d, 10a, and 10c compared to untreated (control), Flupirtine, and L1 -treated CLN3 patient iPSC-derived NPCs at 24 hours. Data points represent mean of at least three experiments ±SEM.

[0018] FIG. 3B shows the dose-response curves of selected compounds 33, 36, 38b, 41 b-c, 42, 49, and 50 compared to untreated (control) and Flupirtine-treated CLN3 patient iPSC-derived NPCs at 24 hours. Data points represent mean of at least three experiments ±SEM.

[0019] FIG. 4A shows microscopic fluorescence images of CytolD autophagic detection in CLN3 patient iPSC-derived NPCs.

[0020] FIG. 4B shows quantification using mean fluorescence intensity to represent the increase in measured autophagy. Values represent mean values ±SD from a minimum of at least 7 replicates. Statistics: Unpaired t test. *, p <0.05, **, p <0.01, ***, p <0.001.

[0021] FIG. 5 shows the results of screening of compound ability to clear SCMAS accumulation after 24 hours at 10 μM concentration in CLN3 Patient iPSC-derived NPCs. Values represent mean values ± SEM from a minimum of at least 2 experiments. Statistics: Unpaired t test. *, p <0.05, **, p <0.01.

[0022] FIG. 6A shows a chart depicting the effect of Retigabine, L1, and compound 9b to activate Kv7.2 / Kv7.3 voltage-gated potassium channels normalized to vehicle control (100%) at 1 μM concentration using a manualDocket No. 31196 / 25102 / PCpatch clamp electrophysiology. Values represent mean values ± SD from repeat experiments. Statistics:Unpaired t test. *, p <0.05, ****, p <0.0001

[0023] FIG. 6B shows a chart depicting the effect of Retigabine, L1, and compound 9b to activate Kv7.2 / Kv7.3 voltage-gated potassium channels normalized to vehicle control (100%) at 10 μM concentration using a manual patch clamp electrophysiology. Values represent mean values ± SD from repeat experiments. Statistics:Unpaired t test. *, p <0.05, ****, p <0.0001DETAILED DESCRIPTION

[0024] Provided herein are compounds and methods for the treatment of a variety of diseases. In certain embodiments, provided are small molecules useful for the treatment of neurodegenerative disorders. The compounds display particular efficacy in disorders associated with mutations in the CLN3 gene, without being broken down into toxic metabolites.Compounds of the Disclosure

[0025] The present disclosure describes compositions of matter and methods for the treatment of potentially a variety of diseases. In certain embodiments, the compounds may be effective in treating neurodegenerative disorders. In certain embodiments, the compounds may be used to treat one or more of a variety of diseases including but not limited to CLN3 diseases, CLN6 diseases, a lysosomal storage disorders, Alzheimer's disease, Parkinson's disease, a neurodevelopmental disorder, traumatic brain injury, stroke, Amyotrophic Lateral Sclerosis, Huntington's disease, ischemia, attention deficit disorder, or epilepsy.

[0026] Previously-reported analogs of the non-opioid analgesics Flupirtine and Retigabine have been approved by the United States Food and Drug Administration for the treatment of pain after surgery and / or the treatment of seizures, and exhibit neuroprotective effects. However, Flupirtine has been restricted for use in the European Union (EU) due to drug-induced liver toxicity resulting from formation of a toxic metabolite. The triaminoaryl moiety within the Flupirtine and Retigabine structure is oxidized to a reactive azaquinone diimine or quinone diimine metabolite, respectively, which can result in the formation of a phenazinium salt from Retigabine, and toxic hapten-protein adducts from Flupirtine. Flupirtine-induced hepatotoxicity, though rare, is linked to enzymatic oxidation processes that generate reactive intermediates. While the precise mechanisms remain unclear, evidence suggests that peroxidase-mediated oxidation of Flupirtine produces azaquinone diimine metabolites, as evidenced by in vitro detection of glutathione conjugates and clinical identification of urinary mercapturic acid derivatives. These reactive intermediates can covalently modify endogenous macromolecules, directly inducing cellular injury, or acting as haptens that provoke adaptive immune responses. In contrast, Retigabine's metabolism is dominated by phase II reactions, particularly N-glucuronidation with no evidence of hepatic metabolism. Retigabine undergoes oxidation through an extrahepatic pathway mediated by melanin. Retigabine is oxidized to yield quinone diimine intermediates, which dimerize into phenazinium structures- a reaction observed in melanin-containing tissues like the retina. These phenazinium compounds are strongly associated with blue tissue discoloration, as evidenced by their detection via MALDI imaging in melanin-richDocket No. 31196 / 25102 / PCocular tissues of animal models. The absence of such discoloration in albino rats lacking melanin further supports melanin's catalytic role in this pathway.

[0027] Previous studies have focused on increasing neuroprotective effects while concomitantly reducing formation of the toxic metabolite. This effort led to the identification of a first-generation compound, L1, which showed no apparent liver injury in mouse pathology and blood chemistry, and demonstrated significant effect to increase the expression of the anti-apoptotic protein Bcl-2, rescue mitochondrial dysfunction, and clear accumulated subunit c of mitochondrial ATP synthase by activation of autophagy in a CLN3 patient-derived iPSC model. A general scheme showing the conversion of Flupirtine, Retigabine, and L1 to toxic intermediates is shown in Scheme 1.Scheme 1Toxic Metabolites

[0028] Without wishing to be bound by any particular theory, the compounds disclosed herein are second-generation compounds comprising cyclized 1 H-benzo[d]imidazoles and heterocyclic isosteres that cannot form the quinone diamine or azaquinone diimine toxicophores that result from the parent structures. This strategy led to the identification of a series of compounds which show further improvement in protecting cell viability loss in CLN3 patient-derived iPSCs and 'drug-like' properties after oral dosing. Mechanism of action studies showed that these compounds do not possess the potassium channel activation effects of the parent Flupirtine and Retigabine agents but do work to activate autophagy and clear subunit c accumulation from iPSC-derived neural progenitor cells.Docket No. 31196 / 25102 / PC

[0029] In certain embodiments, the compounds may include but are not limited benzoimidazole derivatives. In some embodiments, the compounds include but are not limited to the following.

[0030] The present disclosure in its various embodiments may describe novel chemical compositions, methods of treating disease or disorders, and / or methods of treating a disease or disorder in a subject associated with neurological disorders and diseases that include but are not limited to with the accumulation of subunit c of mitochondrial ATP synthase, impaired autophagy, or other like characteristics. The compositions may be used to treat disease or disorders such as, but not limited to, CLN3 disease (aka Batten Disease), CLN6 disease, lysosomal storage disorders, Alzheimer's disease, Parkinson's disease, neurodevelopmental disorders, traumatic brain injury, stroke, Amyotrophic Lateral Sclerosis, Huntington's disease, ischemia, attention deficit disorders, and epilepsy. The compositions of the present disclosure may be used to treat cells, where such cells may be human, mammalian, or other like organisms.

[0031] In one embodiment, the disclosure provides compositions comprising cyclized 1 H-benzo[d]imidazoles or like molecules. The compositions may be comprising of heterocyclic isosteres or like molecules. The compositions may be comprising of cyclized 1H-benzo[d]imidazoles, heterocyclic isosteres, other like molecules or a combination thereof. The composition may be unable to form the quinone diamine, azaquinone diimine toxicophores or other like molecules. The compositions may enhance protecting cell viability loss. The compositions may be used as a therapeutic. The compositions may be used as a treatment to protect cells from the effects of neurodegenerative diseases, disorders or other like indications. The compositions may activate autophagy in a cell. The compositions may clear subunit c accumulation from cells.

[0032] Provided herein are compounds having the structure of Formula (0):wherein X = O, NH, N-Alkyl, N-Cycloalkyl, S, SO2, SO or phosphate; RI = CF3, OCF3, SCF3 or other electron-withdrawing or donating substituent at the ortho, meta or para position. Including bi-, tri- and tetra- substitution; R2= Alkyl or cycloalkyl; and R3 = Alkyl, cycloalkyl, heterocycle, aromatic, substituted aromatic, benzyl, substituted benzyl, including ether, amine, carbamate, and thioether linkers, amide, sulphonamide and urea-containing linkers.

[0033] Also provided herein are compounds and pharmaceutically acceptable salts thereof having the structure of Formula (I):Docket No. 31196 / 25102 / PCwhereinring A is a 5-membered heteroaryl moiety comprising 1 or 2 ring heteroatoms each independently selected from 0, N, and S;R1is H, halo, Ci-ehaloalkyl, -O-Ci-ehaloalkyl, or -S-Ci-ehaloalkyl;L is -Ci.3alkylene-O-, -Ci.3alkylene-NR3-, -Ci.3alkylene-C(O)NH-, -Ci.3alkylene-NHC(O)NH-, -C(0)-, or -CH(OH)-; R2is H, -Ci.3alkyl, SH, -Ci.3alkylene-OH, -NHC(O)O-Ci-3alkyl, -Co.3alkylene-C6-ioaryl, -Co-3alkylene-(5-6 membered heteroaryl) wherein the heteroaryl comprises 1 or 2 heteroatoms each independently selected from 0, N, and S, or -Co-3alkylene-0-Co-3alkylene-C6-ioaryl, and in each instance the aryl is substituted with 0, 1, or 2 substituents selected from halo and-O-Ci-3haloalkyl; andR3is H or -Co-3alkylene-C6-ioaryl, and the aryl is substituted with 1 substituent selected from halo and -Ci.3haloalkyl.

[0034] In some cases, ring A is a 5-membered heteroaryl moiety comprising 1 ring heteroatom selected from 0, N, and S. In some cases, ring A is a 5-membered heteroaryl moiety comprising 2 ring heteroatoms each independently selected from 0, N, and S. In some cases, ring A is a 5-membered heteroaryl moiety comprising at least 1 ring N heteroatom. In some cases, ring A is a 5-membered heteroaryl moiety comprising 1 ring N heteroatom. In some cases, ring A is a 5-membered heteroaryl moiety comprising 2 ring N heteroatoms. In some cases, ring A is a 5-membered heteroaryl moiety comprising 1 ring N heteroatom and 1 ring S or 0 heteroatom. In some cases, ring A is a 5-membered heteroaryl moiety comprising 1 ring N heteroatom and 1 ring S heteroatom. In some cases, ring A is a 5-membered heteroaryl moiety comprising 1 ring N heteroatom and 1 ring 0 heteroatom. In some cases, ring A is pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, or oxazolyl. In some cases, ring A is imidazolyl, pyrazolyl, or thiazolyl. In some cases, ring A is imidazolyl or thiazolyl. In some cases, ring A is pyrrolyl. In some cases, ring A is imidazolyl. In some cases, ring A is pyrazolyl. In some cases, ring A is thiazolyl.Docket No. 31196 / 25102 / PC

[0035] In some cases, R2is H, -C1-3alkyl, or -C1-3alkylene-OH. In some cases, R2is H. In some cases, R2is -Ci-3alkyl. In some cases, R2is CH3. In some cases, R2is-Ci-salkylene-OH. In some cases, R2is CH2-OH. In some cases, R2is -NHC(0)0-Ci-3alkyl. In some cases, R2is NHC(O)O-CH2CH3. In some cases R2is SH. In some cases, R2is -Co-salkylene-Ce-ioaryl or a -Co-3alkylene-(5-6 membered heteroaryl), wherein the heteroaryl comprises 1 or 2 heteroatoms each independently selected from 0, N, and S, wherein the aryl is substituted with 0, 1, or 2 substituents selected from halo and -O-Ci-shaloalkyl. In some cases, R2is -Co-aalkylene-Ce-ioaryl wherein the aryl is substituted with 0, 1, or 2 substituents selected from halo and -O-Ci-shaloalkyl. In some cases, R2is CoalkyleneCe-ioaryl. In some cases, the aryl is substituted with 0 substituents. In some cases, the aryl is substituted with 1 substituent selected from halo and -O-Ci-shaloalkyl. In some cases, the aryl is substituted with 2 substituents selected from halo and -O-Ci-shaloalkyl. In some cases, R2is CoalkyleneCearyl wherein the aryl is substituted with 0 substituents. In some cases, R2is CoalkyleneCearyl wherein the aryl is substituted with 1 substituent selected from halo and -O-Ci-shaloalkyl. In some cases, R2is CoalkyleneCearyl wherein the aryl is substituted with 2 substituents selected from halo and -O-Ci-shaloalkyl. In some cases, R2is CialkyleneCe-waryl wherein the aryl is substituted with 0, 1, or 2 substituents selected from halo and -O-C1-shaloalkyl. In some cases, R2is CialkyleneCearyl wherein the aryl is substituted with 0, 1, or 2 substituents selected from halo and -O-Ci-shaloalkyl. In some cases, R2is CialkyleneCearyl wherein the aryl is substituted with 1 substituent selected from halo and -O-Ci-shaloalkyl. In some cases, R2is CialkyleneCearyl wherein the aryl is substituted with 2 substituents selected from halo and -O-Ci-shaloalkyl. In some cases, at least 1 substituent is halo. In some cases, each substituent is halo. In some cases, at least 1 substituent is Cl. In some cases, each substituent is Cl. In some cases, at least 1 substituent is Br. In some cases, each substituent is Br. In some cases, at least 1 substituent is -O-Ci-shaloalkyl. In some cases, each substituent is -O-Ci-shaloalkyl. In some cases, at least 1 substituent is OCF3. In some cases, each substituent is OCF3. In some cases, R2is phenyl substituted with Cl or Br. In some cases, R2is phenyl substituted with 1 Cl. In some cases, R2is phenylDocket No. 31196 / 25102 / PCsubstituted with 2 F or -CF -phenyl substituted with OCF3. In some cases, R2is -CF -phenyl substituted with 2F. In some cases, R2is -CF -phenyl substituted with OCF3. In some cases,. in some cases, R2isvC F. In some cases, R2is Q0CF3. In some cases, R2is -Co-3alkylene-(5-6 membered heteroaryl) wherein the heteroaryl comprises 1 or 2 heteroatoms each independently selected from 0, N, and S. In some cases, R2is a Coalkylene-(5-6 membered heteroaryl). In some cases, R2is a Coalkylene-(6 membered heteroaryl) with 1 N heteroatom. In some cases, R2is pyridyl. Insome cases, R2isIn some cases, R2is -Co-salkylene-O-Co-salkylene-Ce-ioaryl. In some cases, R2is - Co-3alkylene-0-Co-3alkylene-phenyl. In some cases, R2is -Cialkylene-0-Cialkylene-C6-ioaryl. In some cases, R2is -CH2-O-CH2-phenyl. In some cases, R2is H, SH, CH3, CH2-OH, -NHC(O)O-CH2CH3, pyridyl, phenyl substituted with Cl or Br, -CF phenyl substituted with 2 F, -CF -phenyl substituted with OCF3, or -CFh-O-CFh-phenyl.cases, ring A and its R2substituents form. In some cases, ring A and its R2substituents formIn some cases, ring A and its R2substituents formsome cases, ringDocket No. 31196 / 25102 / PCA and its R2substituents form. In some cases, ring A and its R2substituents formsome cases, ring A and its R2substituents form. In some cases, ring A and its R2substituents formIn some cases, ring A and its R2substituents formn some cases, ring A and its R2substituents formIn some cases,nts formsome cases, ring A and its R2substituents formsome cases, ring A and its R2substituents formIn some cases, ring A andits R2substituents formIn some cases, ring A and its R2substituents formcases, ring A and its R2substituents form. In some cases, ring A and its R2substituents form

[0037] In some cases, R1is H. In some cases, R1is halo, C1-6haloalkyl, -O-C1-6haloalkyl, or -S-C1-6haloalkyl. In some cases, R1is halo, C1-6haloalkyl, or -O-C1-6haloalkyl. In some cases, R1is halo. In some cases, R1is F. In some cases, R1is C1-6haloalkyl. In some cases, R1is Cihaloalkyl. In some cases, R1is CF3. In some cases, R1is -O-C1-6haloalkyl. In some cases, R1is -O-Cihaloalkyl. In some cases, R1is OCF3. In some cases, R1is F, CF3, or OCF3. In some cases, R1is -S-C1-6haloalkyl. In some cases, R1is -S-Cihaloalkyl. In some cases, R1is SCF3.

[0038] In some cases, L is -Ci-3alkylene-O- or -Ci-salkylene-NR3-. In some cases, L is -C1-3alkylene-O-. In some cases, L is -Cialkylene-O-. In some cases, L is -CH2O-. In some cases, L is -C1-3alkylene-NR3-. In some cases, L is -Cialkylene-NR3-. In some cases, L is -Cialkylene-NH-. In some cases, L is -CH2NH-. In some cases,Docket No. 31196 / 25102 / PCL is -Ci-3alkylene-C(0)NH-. In some cases, L is -CH2-C(0)NH-. In some cases, L is -Ci-3alkylene-NHC(0)NH-. In some cases, L is -CH2-NHC(0)NH-. In some cases, L is -C(0)-. In some cases, L is CH(OH)-.

[0039] In some cases, R3is H. In some cases, R3is -Co-aalkylene-Ce-ioaryl and the aryl is substituted with 1 substituent selected from halo and -Ci-shaloalkyl. In some cases, R3is -Ci-3alkylene-Ce-ioaryl and the aryl is substituted with 1 substituent selected from halo and -Ci-3haloalkyl. In some cases, R3is -Ci-3alkylene-Ce-ioaryland the aryl is substituted with 1 halo substituent. In some cases, R3is. in some cases, R3is - Ci-3alkylene-C6-ioaryl and the aryl is substituted with 1 -Ci-shaloalkyl substituent. In some cases, R3is. In some cases, In some cases, R3is.

[0040] In some cases, L and R3together arearesome cases, L and R3together aresome cases, L and R3together areIn some cases, L and R3together areIn some cases, L and R3together areIn some cases, L and R3together areIn some cases, L and R3together areDocket No. 31196 / 25102 / PC

[0041] In some cases, the compounds and pharmaceutically acceptable salts thereof have a structureselected from any one of Formulaesome cases, the compounds and pharmaceutically acceptable salts thereof have a structure selected from Formulae (II) and (III). In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure of Formula (II). In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure of Formula (III). In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure of Formula (IV). In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure of Formula (V). In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure of Formula (VI). In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure of Formula (VII). In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure of Formula (VIII). In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure of Formula (IX). In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure of Formula (X).

[0042] In some cases, the compounds and pharmaceutically acceptable salts thereof have a structure shown in Table A.Table A:Docket No. 31196 / 25102 / PCDocket No. 31196 / 25102 / PCDocket No. 31196 / 25102 / PCDocket No. 31196 / 25102 / PCDocket No. 31196 / 25102 / PC

[0043] In some cases, the compound is 9b or 38b, or a pharmaceutically acceptable salt thereof. In some cases, the compound is 9b, or a pharmaceutically acceptable salt thereof. In some cases, the compound is 38b, or a pharmaceutically acceptable salt thereof.

[0044] The compounds disclosed herein can be in the form of a pharmaceutically acceptable salt. As used herein, the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this disclosure include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, trifluoroacetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, glutamate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate,Docket No. 31196 / 25102 / PCthiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base. Such salts include, but are not limited to, alkali metal, alkaline earth metal, aluminum salts, ammonium, N+(Ci-4alkyl)4 salts, and salts of organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N, N'-dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine, dehydroabietylamine, N, N'-bisdehydroabietylamine, glucamine, N-methylglucamine, collidine, quinine, quinoline, and basic amino acids such as lysine and arginine. This disclosure also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.Definitions

[0045] As used herein, the term "alkyl” refers to straight chained and branched saturated hydrocarbon groups containing one to six carbon atoms. The term Cnmeans the alkyl group has “n” carbon atoms. For example, Ce alkyl refers to an alkyl group that has 6 carbon atoms. Ci-Ce alkyl refers to an alkyl group having a number of carbon atoms encompassing the entire range (e.g., 1 to 6 carbon atoms), as well as all subgroups (e.g., 1-6, 1-5, 3-6, 1, 2, 3, 4, 5, and 6 carbon atoms). Nonlimiting examples of alkyl groups include, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl (2-methylpropyl), and t-butyl (1,1 -dimethylethyl). Unless otherwise indicated, an alkyl group can be an unsubstituted alkyl group or a substituted alkyl group as defined herein.

[0046] The term “haloalkyl,” means an alkyl, as defined above, that is substituted with one or more, e.g., one to five halogen atoms and includes monohaloalkyl and polyhaloalkyl. For example, the term “C1-6 haloalkyl” includes trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0047] The term "alkylene” refers to a straight or branched, saturated hydrocarbon radical having the number of carbon atoms indicated, and linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the alkylene can be linked to the same atom or different atoms of the alkylene group.Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene and hexylene.

[0048] As used herein, the term "halo” or "halogen” refers to fluorine, chlorine, bromine, or iodine.

[0049] As used herein, the term "aryl” refers to a mono- or polycyclic aromatic group having 6-10 carbon atoms. Unless otherwise indicated, an aryl group can be unsubstituted or substituted as defined herein. Aryl groups can be isolated (e.g., phenyl) or fused to another aryl group (e.g., naphthyl, anthracenyl). Exemplary aryl groups include, but are not limited to, phenyl, naphthyl, and the like.Docket No. 31196 / 25102 / PC

[0050] As used herein, "heteroaryl” refers to a 5-membered monocyclic aromatic ring having 1 or 2 ring heteroatoms each independently selected from 0, N, and S. In some embodiments, the heteroaryl ring comprises at least 1 ring nitrogen atom. In some embodiments, the heteroaryl ring comprises 2 ring nitrogen atoms. Non-limiting examples of contemplated heteroaryl groups include pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, and oxazolyl.

[0051] As used herein, the term "substituted,” when used to modify a chemical functional group, refers to the replacement of at least one hydrogen radical on the functional group with a substituent. Substituents are as defined herein. When a chemical functional group includes more than one substituent, the substituents can be bound to the same carbon atom or to two or more different carbon atoms.

[0052] As used herein, the term "therapeutically effective amount” means an amount of a compound or combination of therapeutically active compounds (e.g., a dopamine D4 receptor or sigma-1 receptor modulator) that ameliorates, attenuates or eliminates one or more symptoms of a particular disease or condition (e.g., cancer), or prevents or delays the onset of one of more symptoms of a particular disease or condition.

[0053] As used herein, the terms "patient” and "subject” may be used interchangeably and mean animals, such as dogs, cats, cows, horses, and sheep (e.g., non-human animals) and humans. Particular patients or subjects are mammals (e.g., humans). The terms patient and subject include males and females.

[0054] As used herein, the term "pharmaceutically acceptable” means that the referenced substance, such as a compound of the present disclosure, or a formulation containing the compound, or a particular excipient, are safe and suitable for administration to a patient or subject. The term "pharmaceutically acceptable excipient” refers to a medium that does not interfere with the effectiveness of the biological activity of the active ingredient(s) and is not toxic to the host to which it is administered.

[0055] As used herein the terms "treating”, "treat” or "treatment” and the like include preventative (e.g., prophylactic) and palliative treatment.

[0056] As used herein, the term "excipient” means any pharmaceutically acceptable additive, carrier, diluent, adjuvant, or other ingredient, other than the active pharmaceutical ingredient (API).Synthesis of Compounds of the Disclosure

[0057] The compounds disclosed herein can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as Smith, M. B., March, J., March' s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5thedition, John Wiley & Sons: New York, 2001; and Greene, T. W., Wuts, P. G. M., Protective Groups in Organic Synthesis, 3rdedition,Docket No. 31196 / 25102 / PCJohn Wiley & Sons: New York, 1999, are useful and recognized reference textbooks of organic synthesis known to those in the art. For example, the compounds disclosed herein can be synthesized by solid phase synthesis techniques including those described in Merrifield, J. Am. Chem. Soc. 1963; 85:2149; Davis et al., Biochem. Inti.1985; 10:394-414; Larsen et al., J. Am. Chem. Soc. 1993; 115:6247; Smith et al., J. Peptide Protein Res. 1994; 44: 183; O'Donnell et al., J. Am. Chem. Soc. 1996; 118:6070; Stewart and Young, Solid Phase Peptide Synthesis,, Freeman (1969); Finn et al., The Proteins, 3rd ed., vol. 2, pp. 105-253 (1976); and Erickson et al., The Proteins, 3rd ed., vol. 2, pp. 257-527 (1976). The following descriptions of synthetic methods are designed to illustrate, but not to limit, general procedures for the preparation of compounds of the present disclosure.

[0058] The synthetic processes disclosed herein can tolerate a wide variety of functional groups; therefore, various substituted starting materials can be used. The processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt, ester or prodrug thereof.

[0059] Additional synthetic procedures for preparing the compounds disclosed herein can be found in the Examples section.Pharmaceutical Formulations, Dosing, and Routes of Administration

[0060] Further provided are pharmaceutical formulations comprising a compound as described herein (e.g., compounds of Formula (I) - (X), compounds of Table A, or pharmaceutically acceptable salts of the compounds) and a pharmaceutically acceptable excipient.

[0061] The compositions may be administered to a subject by any method. Methods of administration include but are not limited to parenterally, subcutaneously, orally, topically, pulmonarily, rectally, vaginally, intravenously, intraperitoneally, intrathecally, intracerebrally, epidurally, intramuscularly, intradermally, or intracarotidly.

[0062] The compositions administered to a subject may be conveniently formulated for administration with one or more pharmaceutically acceptable carrier(s).

[0063] The compounds described herein can be administered to a subject in a therapeutically effective amount (e.g., in an amount sufficient to prevent or relieve the symptoms of a disease or disorder). The compounds can be administered alone or as part of a pharmaceutically acceptable composition or formulation. In addition, the compounds can be administered all at once, multiple times, or delivered substantially uniformly over a period of time. It is also noted that the dose of the compound can be varied over time.

[0064] A particular administration regimen for a particular subject will depend, in part, upon the compound, the amount of compound administered, the route of administration, and the cause and extent of any side effects. The amount of compound administered to a subject (e.g., a mammal, such as a human) in accordance with the disclosure should be sufficient to effect the desired response over a reasonable time frame. Dosage typically depends upon the route, timing, and frequency of administration. Accordingly, the clinician titers the dosage andDocket No. 31196 / 25102 / PCmodifies the route of administration to obtain the optimal therapeutic effect, and conventional range-finding techniques are known to those of ordinary skill in the art.

[0065] Suitable methods of administering a physiologically-acceptable composition, such as a pharmaceutical composition comprising the compounds disclosed herein (e.g., compounds of Formula (I) - (X), compounds of Table A, or pharmaceutically acceptable salts of the compounds), are well known in the art. Although more than one route can be used to administer a compound, a particular route can provide a more immediate and more effective reaction than another route. Depending on the circumstances, a pharmaceutical composition comprising the compound is applied or instilled into body cavities, absorbed through the skin or mucous membranes, ingested, inhaled, and / or introduced into circulation. For example, in certain circumstances, it will be desirable to deliver a pharmaceutical composition comprising the agent orally, through injection by intravenous, intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraarterial, intraportal, intralesional, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, urethral, vaginal, or rectal means, by sustained release systems, or by implantation devices. If desired, the compound is administered regionally via intrathecal administration, intracerebral (intra-parenchymal) administration, intracerebroventricular administration, or intraarterial or intravenous administration feeding the region of interest. Alternatively, the composition is administered locally via implantation of a membrane, sponge, or another appropriate material onto which the desired compound has been absorbed or encapsulated. Where an implantation device is used, the device is, in one aspect, implanted into any suitable tissue or organ, and delivery of the desired compound is, for example, via diffusion, timed-release bolus, or continuous administration.

[0066] To facilitate administration, the compound is, in various aspects, formulated into a physiologically-acceptable composition comprising a carrier (e.g., vehicle, adjuvant, or diluent). The particular carrier employed is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the compound, and by the route of administration. Physiologically- acceptable carriers are well known in the art. Illustrative pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (for example, see U.S. Patent No. 5,466,468). Injectable formulations are further described in, e.g., Pharmaceutics and Pharmacy Practice, J. B. Lippincott Co., Philadelphia. Pa., Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986)). A pharmaceutical composition comprising the compound is, in one aspect, placed within containers, along with packaging material that provides instructions regarding the use of such pharmaceutical compositions. Generally, such instructions include a tangible expression describing the reagent concentration, as well as, in certain embodiments, relative amounts of excipient ingredients or diluents (e.g., water, saline or PBS) that may be necessary to reconstitute the pharmaceutical composition.

[0067] Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution intoDocket No. 31196 / 25102 / PCsterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0068] These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Microorganism contamination can be prevented by adding various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of injectable pharmaceutical compositions can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0069] Solid dosage forms for oral administration include capsules, tablets, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, mannitol, and silicic acid; (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) humectants, as for example, glycerol; (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (a) solution retarders, as for example, paraffin; (f) absorption accelerators, as for example, quaternary ammonium compounds; (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate; (h) adsorbents, as for example, kaolin and bentonite; and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, and tablets, the dosage forms may also comprise buffering agents. Solid compositions of a similar type may also be used as fillers in soft and hard filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols, and the like.

[0070] Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. The solid dosage forms may also contain opacifying agents. Further, the solid dosage forms may be embedding compositions, such that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner.Examples of embedding compositions that can be used are polymeric substances and waxes. The active compound can also be in micro-encapsulated form, optionally with one or more excipients.

[0071] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, cornDocket No. 31196 / 25102 / PCgerm oil, olive oil, castor oil, and sesame seed oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, or mixtures of these substances, and the like.

[0072] Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. Suspensions, in addition to the active compound, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, or mixtures of these substances, and the like.

[0073] Compositions for rectal administration are preferably suppositories, which can be prepared by mixing the compounds of the disclosure with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary room temperature, but liquid at body temperature, and therefore, melt in the rectum or vaginal cavity and release the active component.

[0074] Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.

[0075] The frequency of dosing will depend on the pharmacokinetic parameters of the agents and the routes of administration. The optimal pharmaceutical formulation will be determined by one of skill in the art depending on the route of administration and the desired dosage. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990) Mack Publishing Co., Easton, PA, pages 1435-1712, incorporated herein by reference. Such formulations may influence the physical state, stability, rate of in vivo release and rate of in vivo clearance of the administered agents. Depending on the route of administration, a suitable dose may be calculated according to body weight, body surface areas or organ size. Further refinement of the calculations necessary to determine the appropriate treatment dose is routinely made by those of ordinary skill in the art without undue experimentation, especially in light of the dosage information and assays disclosed herein, as well as the pharmacokinetic data observed in animals or human clinical trials.

[0076] The precise dosage to be employed depends upon several factors including the host, whether in veterinary medicine or human medicine, the nature and severity of the condition, e.g., disease or disorder, being treated, the mode of administration and the particular active substance employed. The compounds may be administered by any conventional route, in particular enterally, and, in one aspect, orally in the form of tablets or capsules. Administered compounds can be in the free form or pharmaceutically acceptable salt form as appropriate, for use as a pharmaceutical, particularly for use in the prophylactic or curative treatment of a disease of interest. These measures will slow the rate of progress of the disease state and assist the body in reversing the process direction in a natural manner.Docket No. 31196 / 25102 / PC

[0077] It will be appreciated that the pharmaceutical compositions and treatment methods of the disclosure are useful in fields of human medicine and veterinary medicine. Thus the subject to be treated is in one aspect a mammal. In another aspect, the mammal is a human.

[0078] In jurisdictions that forbid the patenting of methods that are practiced on the human body, the meaning of "administering” of a composition to a human subject shall be restricted to prescribing a controlled substance that a human subject will self-administer by any technique (e.g., orally, inhalation, topical application, injection, insertion, etc.). The broadest reasonable interpretation that is consistent with laws or regulations defining patentable subject matter is intended. In jurisdictions that do not forbid the patenting of methods that are practiced on the human body, the "administering” of compositions includes both methods practiced on the human body and also the foregoing activities.Methods of Use

[0079] The neuronal ceroid lipofuscinoses (NCLs), commonly referred to as Batten Disease, are a family of extremely rare and fatal autosomal pediatric neurodegenerative disorders. These diseases are the most common causes of dementia in the pediatric population, with an incidence rate estimated to be approximately 1 in 12,500. Individual NCLs are generally classified by the gene that is altered in the disorder, resulting in 13 different subtypes. The most common subtype of Batten disease is CLN3, in which there is a mutation in the CLN3 gene that encodes the CLN3 protein. The onset of this disease typically presents between 4-10 years of age with common symptoms including vision impairment and seizures. End-stage symptoms include blindness, spasms, and dementia, with poorly controlled seizures. Death eventually occurs in children with this disease during their teens or early twenties.

[0080] Common pathological hallmarks of CLN3 disease include lipofuscin, a material specifically located in the lysosomes, being accumulated in tissues and fat, and protein deposits in the brain, retina, and other areas. Additional hallmarks include impaired autophagy, accelerated apoptosis, and secondary inflammation. The accumulation of subunit c of mitochondrial ATP synthase (SCMAS) in lysosome-derived organelles has been observed in all the NCLs, although the mechanism is currently unknown. Treatment options such as gene therapy, stem cell therapy, and small molecule therapies have been explored as treatment strategies. However, due to the complex nature of the disease and an incomplete understanding of the functions of the disease-associated proteins, there is no disease modifying therapy, with treatment limited to palliative care.

[0081] A major hurdle in the development of new therapeutics for the treatment of neurological disorders is the difficulty of drugs passing the blood-brain barrier (BBB). This selective physical barrier leads to insufficient drug delivery into the brain, with can result in low therapeutic efficacy. The BBB contains tight-junctions that only passively diffuse lipid-soluble drugs for a size less than 600 Da. This size exclusion and selectivity renders macromolecules essentially unable to cross the BBB while also excluding more than 98% of small molecules from accessing the brain. Small molecule therapeutics have an advantage in the potential treatment of CLN3 disease due to their smaller size compared to biomolecules, lower storage costs, and more palatable routes ofDocket No. 31196 / 25102 / PCadministration. Additionally, in many neurodegenerative disorders, including CLN3 disease, the BBB is disrupted, which may facilitate drug entry. Previous studies have identified common molecular pathways that may be targeted for the treatment of NCLs. Therapeutic entry points, including neuroinflammation, impaired autophagy, endocytic trafficking, impaired calcium homeostasis, and mitochondrial alterations, have all been targeted. However, none have reached clinical stages.

[0082] In CLN3 disease specifically, one postulated function of the CLN3 protein, is the modulation of the anti-apoptotic protein B-cell Lymphoma 2 (Bcl-2). This protein acts as a key regulator of cellular apoptosis by controlling the activation of apoptotic protease (caspase). The CLN3 gene has also been hypothesized to modulate endogenous ceramides, leading to the suppression of apoptosis. The accumulation of lipofuscin and SCMAS in the lysosomes of CLN3 patients also implicates autophagy dysfunction.

[0083] There are limited therapeutic options for neurodegenerative diseases. Flupirtine, a nonopioid analgesic originally approved by the European Union (EU) for the treatment of pain after surgery, and Retigabine, approved by the FDA for the treatment of seizures, exhibit neuroprotective effects. Notably Flupirtine has been restricted for use in the EU due to drug-induced liver toxicity resulting from formation of a toxic metabolite. The triaminoaryl moiety within the Flupirtine and Retigabine structure is oxidized to a reactive azaquinone diimine or quinone diimine metabolite, respectively, which can result in the formation of a phenazinium salt from Retigabine, and toxic hapten-protein adducts from Flupirtine. Flupirtine-induced hepatotoxicity, though rare, is linked to enzymatic oxidation processes that generate reactive intermediates. While the precise mechanisms remain unclear, evidence suggests that peroxidase-mediated oxidation of Flupirtine produces azaquinone diimine metabolites, as evidenced by in vitro detection of glutathione conjugates and clinical identification of urinary mercapturic acid derivatives. These reactive intermediates can covalently modify endogenous macromolecules, directly inducing cellular injury, or acting as haptens that provoke adaptive immune responses. In contrast, Retigabine's metabolism is dominated by phase II reactions, particularly N-glucuronidation with no evidence of hepatic metabolism. Retigabine undergoes oxidation through an extrahepatic pathway mediated by melanin. Retigabine is oxidized to yield quinone diimine intermediates, which dimerize into phenazinium structures- a reaction observed in melanin-containing tissues like the retina. These phenazinium compounds are strongly associated with blue tissue discoloration, as evidenced by their detection via MALDI imaging in melanin-rich ocular tissues of animal models. The absence of such discoloration in albino rats lacking melanin further supports melanin's catalytic role in this pathway. The use of therapeutics that increase neuroprotective effects while concomitantly reducing formation of the toxic metabolite would be advantageous.

[0084] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula (0), (I), Table A, and pharmaceutically acceptable salts of the compounds) may be used for treating and / or preventing diseases in a patient in need thereof. Example diseases include but are not limited to neuronal ceroid lipofuscinoses (including CLN3 disease and CLN6 disease), lysosomal storage disorders, Alzheimer's disease, Parkinson's disease, neurodevelopmental disorders, traumatic brain injury, stroke, Amyotrophic Lateral Sclerosis, Huntington's disease, ischemia, attention deficit disorder, epilepsy, and / or other like diseases or disorders.Docket No. 31196 / 25102 / PC

[0085] Certain compositions of the present disclosure may be used for the treatment of disease or disorders. In one embodiment, the diseases may include but are not limited to neurological disorders and diseases. In one embodiment, neurological disorders and diseases include but are not limited to CLN3 disease (aka Batten Disease), CLN6 disease, lysosomal storage disorders, Alzheimer's disease, Parkinson's disease, neurodevelopmental disorders, traumatic brain injury, stroke, Amyotrophic Lateral Sclerosis, Huntington's disease, ischemia, attention deficit disorders, epilepsy and / or other like diseases or disorders. In one embodiment, the disease is associated with accumulation of subunit c of mitochondrial ATP synthase. In one embodiment, the disease is associated with impaired autophagy. The compositions may be used to treat cells. Such cells may be human, mammalian, or other like organisms. The cells treated by the compositions may be neurological cells.

[0086] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula (I) - (X), Table A, and pharmaceutically acceptable salts of the compounds) are useful in reducing or preventing accumulation of subunit c of mitochondrial ATP synthase in a cell, comprising contacting the cell with a therapeutically-effective amount of the compound or pharmaceutical composition.

[0087] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula (I) - (X), Table A, and pharmaceutically acceptable salts of the compounds) are useful in treating diseases or disorders associated with impaired autophagy. Impaired autophagy has been implicated in the pathogenesis of various neurodegenerative diseases, including neuronal ceroid lipofuscinoses, where defective autophagic flux leads to the accumulation of storage materials such as lipofuscin and SCMAS. The compounds disclosed herein may restore or enhance autophagic function, thereby promoting clearance of accumulated substrates and reducing cellular toxicity.

[0088] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula (I) - (X), Table A, and pharmaceutically acceptable salts of the compounds) are useful in treating neurological diseases or disorders.

[0089] In some embodiments, the disease or disorder is CLN3 disease, CLN6 disease, a lysosomal storage disorder, Alzheimer's disease, Parkinson's disease, a neurodevelopmental disorder, traumatic brain injury, stroke, Amyotrophic Lateral Sclerosis, Huntington's disease, ischemia, attention deficit disorder, or epilepsy, or other like diseases or disorders.. In some embodiments, the disease or disorder is CLN3 disease.

[0090] In another embodiment, it is envisioned that the compositions are used in combination with other drugs including but not limited to additional neurological disease therapeutics, cardiology drugs, antidepressants, antipsychotic drugs, antianxiety drugs, anti-inflammatory drugs, and / or immune-modulatory drugs.

[0091] In some embodiments, treatment of a disease or disorder with the compounds disclosed herein (e.g., compounds of Formula (I) - (X), Table A, and pharmaceutically acceptable salts of the compounds), further comprises administering to the subject a therapeutically-effective amount of one or more additional therapeutic agents. In some embodiments, the compounds disclosed herein may be administered in combination with suchDocket No. 31196 / 25102 / PCadditional therapeutic agents simultaneously, sequentially, or as part of a unified dosing regimen. The selection of additional therapeutic agents may depend on the specific disease or disorder being treated and the individual patient's clinical profile. Combination therapy may provide synergistic or additive therapeutic effects, address multiple pathological mechanisms simultaneously, or allow for dose reduction of individual agents to minimize adverse effects while maintaining efficacy. These additional therapeutic agents include, but are not limited to, neurological disease therapeutics, cardiology drugs, antidepressants, antipsychotic drugs, anti-inflammatory drugs, and immune modulatory drugs.

[0092] The disclosure herein will be understood more readily by reference to the following examples, below.EXAMPLES

[0093] The following examples are provided for illustration and are not intended to limit the scope of the disclosure.Example 1: Synthetic Procedures for Compounds of Formula (I)Synthesis of Compounds 9a-d, 10a-c, and 11

[0094] Compounds 9a-d were synthesized following the method of Procedure A. Compounds 10a-c were synthesized following the method of Procedure B. Compound 11 was synthesized following the method of Procedure C.Procedure A:Docket No. 31196 / 25102 / PC

[0095] Suitably functionalized commercially available benzaldehydes underwent reductive amination with 2-nitrobenzene-1,4-diamine to afford benzylamines. The nitro group of the intermediate was subsequently reduced with tin (II) chloride dehydrate to yield triamine intermediates. These diamines underwent cyclization with either glycolic acid to yield analogues of type 9a (Procedure A) or with commercially available (benzyloxy) acetyl chloride to yield benzyl ether analogues of type 10a (Procedure B). Reductive amination of benzaldehydes with 1 H-indol-4-amine yielded indole analog 11 (Procedure C).(6-((4-fluorobenzyl) amino)-1H-benzo[d]imidazol-2-yl) methanol (9a).

[0096] Yield: 8%. Rf= 0.24 (DCM / MeOH = 9:1).1H NMR (400 MHz, DMSO-d6): 5 11.72 (s, 1H), 7.39 (t, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 1H), 7.11 (t, J= 10.0 Hz, 2H), 6.54 (d, J= 12.0 Hz, 1H), 6.49 (s, 1H), 6.01 (s, 1 H), 5.44 (t, J = 6.0 Hz, 1 H), 4.54 (d, J = 4.0 Hz, 2H), 4.25 (d, J = 4.0 Hz, 2H).13C NMR (100 MHz, DMSO-d6): 5 162.7, 160.3, 137.1, 130.3, 129.8, 129.5, 117.4, 115.5, 115.3, 110.5, 101.3, 58.2, 47.1. HPLC: retention time, 1.69 min; purity, 100%. HRMS (ESI) m / z calculated for C15H14FN3O [M + H]+ 272.1194 found 272.1198.(6-((4-(trifluoromethyl) benzyl) amino)-1H-benzo[d]imidazol-2-yl) methanol (Compound 9b)

[0097] Yield: 7%. Rf= 0.48 (DCM / MeOH = 9:1).1H NMR (400 MHz, DMSO-d6): 5 11.74 (s, 1H), 7.67 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 1H), 6.57 (d, J = 8.0 Hz, 1H), 6.48 (s, 1H), 6.17 (s, 1H), 5.51 (s, 1H), 4.57 (s, 2H), 4.39 (d, J = 4.0 Hz, 2H).13C NMR (100 MHz, DMSO-d6): 5 148.2, 146.3, 144.7, 128.9, 127.5, 126.2, 125.6, 123.5, 120.8, 114.5, 110.6, 101.2, 58.2, 47.4 HPLC- retention time, 1.64 min; Purity 100%. HRMS (ESI) m / z calculated for C16H14F3N3O [M + H]+322.1162 found 322.1167.(6-((4-(trifluoromethoxy) benzyl) amino)-1H-benzo[d]imidazol-2-yl) methanol (Compound 9c)

[0098] Yield: 9%. Rf= 0.33 (DCM / MeOH = 9:1).1H NMR (400 MHz, DMSO-d6): 5 11.76 (s, 1H), 7.49 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.0 Hz, 1 H), 6.56 (d, J = 8.0 Hz, 1 H), 6.50 (s, 1 H), 6.07 (s, 1 H), 5.48 (s, 1H), 4.55 (d, J = 4.0 Hz, 2H), 4.30 (d, J = 4.0 Hz, 2H).13C NMR (100 MHz DMSO-d6): 5 147.4, 144.8, 140.7, 137.9, 132.2, 129.4, 127.9, 121.3, 119.3, 114.1, 110.6, 101.4, 58.2, 47.1 HPLC- retention time, 1.69 min; Purity 99%. HRMS (ESI) m / z calculated for C16H14F3N3O2[M + H]+338.1111 found 338.1119.(6-((4-((trifluoromethyl)thio) benzyl) amino)-1H-benzo[d]imidazol-2-yl) methanol (Compound 9d)

[0099] Yield: 4%. Rf= 0.45 (DCM / MeOH = 9:1).1H NMR (400 MHz, DMSO-d6): 5 11.79 (s, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.0 Hz, 1 H), 6.56 (d, J = 8.0 Hz, 1 H), 6.49 (s, 1 H), 6.13 (s, 1 H), 5.48 (s, 1H), 4.55 (s, 2H), 4.36 (s, 2H).13C NMR (100 MHz, DMSO-d6): 5 153.0, 145.4, 144.8, 136.7, 131.7, 129.1, 128.6, 121.0, 118.2, 115.5, 110.6, 103.5, 58.1, 47.3. HPLC- retention time, 1.68 min; Purity 100%. HRMS (ESI) m / z calculated for C16H14F3N3OS [M + H]+354.0882 found 354.0889.2-((benzyloxy)methyl)-N-(4-fluorobenzyl)-1H-benzo[d]imidazol-6-amine (Compound 10a)

[0100] Yield: 37.9 mg.1H NMR (600 MHz, MeOD-d4)- 57.34-7.24 (10H, m), 6.99-6.96 (2H, m), 6.69 (1H, dd, J = 2.4, J = 1.8), 6.64 (1H, d, J = 2.4), 4.63 (2H, s), 4.54 (2H, s), 4.26 (2H, s).13C NMR (150MHz, MeOD-d4)- 5 164.0, 162.4, 150.8, 146.8, 138.9, 137.3, 137.3, 130.2, 130.1, 129.4, 129.4, 129.0, 128.9, 117.4, 116.0, 115.9,Docket No. 31196 / 25102 / PC113.4, 96.5, 73.8, 66.3. HPLC- retention time, 2.21 min; Purity 99%. HRMS (ESI) m / z calculated for C22H20FN3O[M + H]+362.1663 found 355.1751.2-((benzyloxy)methyl)-6-((4-(trifluoromethyl)benzyl)oxy)-1H-benzo[d]imidazole (PS-5-33, Compound 10b)

[0101] Yield: 2.0%. Rf= 0.40 (hexane / ethyl acetate = 1 / 1).1H NMR (400 MHz, CDCI3) 57.64 (d, J = 8.1 Hz, 2H), 7.57 (d, J = 8.1 Hz, 2H), 7.48 (d, J = 8.7 Hz, 1 H), 7.40 - 7.30 (m, 5H), 7.08 (s, 1 H), 6.97 (dd, J = 8.8, 2.4 Hz, 1H), 5.16 (s, 2H), 4.82 (s, 2H), 4.64 (s, 2H).13C NMR (100 MHz, CDCI3) 5 155.25, 151.54, 141.42, 137.17, 130.36, 130.04, 128.76, 128.36, 128.17, 127.54, 125.72, 125.68, 125.65, 125.61, 122.88, 112.86, 73.56, 70.02, 66.25. HPLC- retention time, 2.23 min; Purity 97%. HRMS (ESI) m / z calculated for C23H19F3N2O2 [M + H]+413.1472 found 413.0620.2-((benzyloxy)methyl)-N-(4-(trifluoromethoxy)benzyl)-1H-benzo[d]imidazol-6-amine (Compound 10c)

[0102] Yield: 596.5 mg.1H NMR (600 MHz, DMSO-d6)- 57.50-7.31 (12H, m), 6.68 (1H, s), 6.51 (1H, s), 4.66 (2H, s), 4.57 (2H, s), 4.33 (2H, s).13C NMR (150MHz, DMSO-d6)- 5 147.5, 145.7, 140.4, 138.2, 129.4, 128.7, 128.2, 128.1, 121.4, 117.0, 111.9, 94.4, 72.3, 65.3, 46.9. HPLC- retention time, 1.79 min; Purity 98%. HRMS (ESI) m / z calculated for C23H20F3N3O2 [M + H]+428.1580 found 428.1573.N-(4-((trifluoromethyl)thio)benzyl)-1H-indol-4-amine (Compound 11)

[0103] Yield: 16.4%.1H NMR (600 MHz, CDCI3) 58.11 (s, 1H), 7.62 (d, J = 7.9 Hz, 2H), 7.49 (d, J= 8.1 Hz, 2H), 7.11-7.05 (m, 2H), 6.87 (d, 8.1 Hz, 1H), 6.51 (m, 1H), 6.27 (d, 7.6 Hz, 1H), 4.55 (s, 2H)13C NMR (150 MHz, CDCI3) 5 143.0, 140.5, 136.6, 136.5, 128.5, 123.4, 122.8, 122.4, 116.9, 102.2, 100.2, 98.6, 48.0 HPLC-retention time, 2.02 min; Purity 96%. HRMS (ESI) m / z calculated for C16H13F3N2S [M + H]+323.0824 found 322.9966.Synthesis of Compounds 14a-b, 14d, 15a-c, 17, 19b-c, 20, 22, 24, 26a-c, 27a, and 29

[0104] The following compounds were synthesized following the method of Procedure D. In some cases, reactions resulted in the synthesis of two compounds in the same reaction.Procedure D:

[0105] N-alkylation of commercially available substituted benzothiazoles, benzimidazoles, and benzoxazoles were reacted with suitably substituted benzyl bromides. These afforded separable mono- and di-substituted benzothiazoles of type 14a and 15a and 17, benzimidazoles of type 19, compounds 20 and 22, and benzoxazole 24.Docket No. 31196 / 25102 / PC

[0106] Alternatively, / V-alkylation of either commercially available 1H-indazol-6-amine or 1H-indol-6-amine was accomplished with suitably substituted commercial benzyl bromides. These afforded major mono- and minor disubstituted, indazole products of type 26 and 27a and indole product 29.N-(4-fluorobenzyl)benzo[d]thiazol-5-amine (Compound 14a)

[0107] Yield: 20.5%. Rf= 0.25 (hexane / ethyl acetate = 30 / 1 ).1H NMR (600 MHz, CDCI3) 58.87 (s, 1H), 7.67 (d, J = 8.6 Hz, 1 H), 7.34 (q, J = 4.4 Hz, 2H), 7.30 (d, J = 2.3 Hz, 1 H), 7.01 (t, J = 8.7 Hz, 2H), 6.83 (dd, J = 8.7, 2.3 Hz, 1H), 4.50 (s, 1H), 4.35 (s, 2H).13C NMR (150 MHz, CDCI3) 5 163.0, 161.3, 155.0, 154.5, 147.0, 134.5, 134.5, 129.2, 128.1, 122.8, 122.0, 115.6, 115.5, 114.9, 105.1, 47.9. HPLC- retention time, 1.80 min; Purity 100%. HRMS (ESI) m / z calculated for C14H11 FN2S [M + H]+259.0700 found 259.0770.N-(4-fluorobenzyl)-2-methylbenzo[d]thiazol-5-amine (Compound 14b)

[0108] Yield: 12.7%.1H NMR (600 MHz, CDCI3) 57.71 (d, J = 8.7 Hz, 1H), 7.32 (dd, J = 8.5, 5.5 Hz, 2H), 7.02 (t, J = 8.6 Hz, 1 H), 6.93 (d, J = 2.4 Hz, 1 H), 6.75 (dd, J = 8.7, 2.4 Hz, 1 H), 4.31 (s, 2H), 2.73 (s, 3H).13C NMR (151 MHz, CDCI3) 5 163.0, 162.4, 161.4, 146.22, 145.54, 137.60, 134.58, 134.56, 129.13, 129.08, 122.73, 115.68, 115.53, 114.19, 102.82, 48.06, 19.85. HPLC- retention time, 1.96 min; Purity 95%. HRMS (ESI) m / z calculated for C15H 13FN2S [M + H]+273.0856 found 273.0943.2-methyl-W-(4-(trifluoromethyl) benzyl) benzo[d]thiazol-5-amine (Compound 14d)

[0109] Yield: 15.7%.1H NMR (600 MHz, CDCI3) 58.89 (s, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.60 (d, J= 7.8 Hz, 4H), 7.434 (s, 1H), 7.40 (t, 11.1 Hz, 1H), 6.94 (dd, J = 2.4, 2.4 Hz, 1H), 4.80 (s, 4H)13C NMR (151 MHz, CDCI3) 5 156.2, 154.3, 147.9, 143.2, 129.1, 128.9, 127.1, 125.2, 125.2, 122.1, 122.0, 113.8, 105.3, 54.8 HPLC- retention time, 3.32 min; Purity 100%. HRMS (ESI) m / z calculated for C16H13F3N2S [M + H]+323.0824 found 323.0840. N,N-bis(4-fluorobenzyl) benzo[d]thiazol-5-amine (Compound 15a)

[0110] Yield: 35.7%. Rf= 0.30 (hexane / ethyl acetate = 30 / 1).1H NMR (600 MHz, CDCI3) 58.86 (s, 1H), 7.68 (d, J = 8.4 Hz, 1 H), 7.46 (d, J = 1.8 Hz, 1 H), 7.22 (q, 4.6 Hz, 4H), 7.00 (t, 8.4 Hz, 4H), 6.96 (dd, J = 2.4, 1.8 Hz, 1H), 4.66 (s, 4H)13C NMR (150 MHz, CDCI3) 5 162.8, 161.2, 155.0, 154.8, 148.1, 133.5, 128.4, 128.4, 122.1, 115.7, 113.8, 106.5, 54.4 HPLC- retention time, 3.32 min; Purity 100%. HRMS (ESI) m / z calculated for C21H16F2N2S [M + H]+ 367.1075 found 367.1191.N,N-bis(4-fluorobenzyl)-2-methylbenzo[d]thiazol-5-amine (Compound 15b)

[0111] Yield: 8.41%.1H NMR (600 MHz, CDCI3) 57.74 (d, J = 9.0 Hz, 1H), 7.20 (dd, J = 8.5, 5.4 Hz, 4H), 7.06 (d, J = 2.6 Hz, 1 H), 7.01 (t, J = 8.7 Hz, 4H), 6.91 (dd, J = 9.0, 2.6 Hz, 1 H), 4.61 (s, 4H), 2.73 (s, 3H).13C NMR (150 MHz, CDCI3) 5 162.9, 162.7, 161.2, 146.8, 145.8, 137.8, 133.6, 128.4, 128.3, 122.6, 115.7, 115.6, 113.3, 104.0, 54.3, 19.9. HPLC- retention time, 2.43 min; Purity 95%. HRMS (ESI) m / z calculated for C22H18F2N2S [M + H]+381.1232 found 381.1358.Docket No. 31196 / 25102 / PCA / , A / -bis(4-(trifluoromethyl)benzyl)benzo[d]thiazol-5-amine (Compound 15c)

[0112] Yield: 3.04%.1H NMR (600 MHz, CDCI3) 68.89 (s, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 7.8 Hz, 4H), 7.43 (d, J= 2.4 1H), 7.40 (d, 8.4 Hz, 4H), 6.94 (dd, J= 2.4, 2.4 Hz 1H), 4.680 (s, 4H)13C NMR (150 MHz, CDCI3) 5156.2, 154.3, 147.9, 143.2, 129.1, 128.9, 127.1, 125.2, 125.2, 122.1, 122.0, 113.8, 105.3, 54.8. HPLC-6.96 min; Purity 100%. HRMS (ESI) m / z calculated for C23H16F6N2S [M + H]* 467.1011 found 467.1038.W-(4-(trifluoromethyl)benzyl)benzo[d]thiazol-6-amine (Compound 17)

[0113] Yield: 7.45%.1H NMR (600 MHz, CDCI3) 58.68 (s, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.61 (d, J= 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 7.02 (d, J=2.4, 1H), 6.86 (dd, J= 2.4, 1.8 Hz, 1H), 4.48 (s, 2H)13C NMR (151 MHz, CDCI3) 5 149.7, 146.5, 146.1, 143.1, 136.0,129.9 (q, J = 33 Hz), 127.6, 125.9, 125.8, 124.1, 114.9, 102.6, 48.2. HPLC- retention time, 2.10 min; Purity 100%. HRMS (ESI) m / z calculated for C15H11F3N2S [M + H]+309.0668 found 309.0547.2-methyl-W-(4-(trifluoromethyl) benzyl)-1H-benzo[d]imidazol-6-amine (Compound 19b)

[0114] Yield: 28%. Rf= 0.45 (CH2CI2 / MeOH = 20 / 1).1H NMR (600 MHz, CDCI3): 57.56 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.35 (d, J= 8.4 Hz, 1H), 6.65 - 6.59 (m, 2H), 4.40 (s, 2H), 2.52 (s, 3H).13C NMR (150 MHz, CDCI3): 5 149.6, 144.3, 143.8, 138.1, 132.4, 129.5 (q, J = 31.5 Hz, 1C), 127.5, 125.6 (q, J = 4.5 Hz, 1C), 125.1 (q, J = 270 Hz, 1C), 115.1, 111.1, 95.8, 48.6, 14.6. HPLC- retention time, 1.67 min; Purity 100%. HRMS (ESI) m / z calculated for C16H14F3N3[M + H]+306.1213 found: 306.1265.2-methyl-W-(4-(trifluoromethoxy) benzyl)-1H-benzo[d]imidazol-6-amine (Compound 19c)

[0115] Yield: 66%. Rf= 0.15 (CH2CI2 / MeOH = 10 / 1).1HNMR (600 MHz, CDCI3): 57.36 (dd, J= 8.4, 3.0 Hz, 3 H), 7.15 (d, J = 8.4 Hz, 2 H), 6.67 (d, J = 2.4 Hz,1 H), 6.61 (dd, J= 8.4, 2.4 Hz, 1H), 4.30 (s, 2H), 2.54 (s, 3H).13C NMR (151 MHz, CDCI3): 5 149.8, 148.3, 144.5, 138.3, 138.1, 132.3, 128.7, 123.0 (q, J = 256.5 Hz, 1C), 121.3, 121.1, 119.6, 117.9, 115.9, 111.1, 95.8, 48.3, 14.5. HPLC- retention time, 1.35 min; Purity 100%. HRMS (ESI) m / z calculated for C16H14F3N3O [M + H]* 322.1162 found 322.1161.N, N-bis(4-fluorobenzyl)-2-methyl-1 H-benzo[d]imidazol-6-amine (Compound 20)

[0116] Yield: 76.5%. Rf= 0.30 (CH2CI2 / MeOH = 10 / 1).1H NMR (600 MHz, CDCI3): 57.369 (d, J = 9.0 Hz, 1H), 7.25 - 7.19 (m, 4H), 7.03 - 6.96 (m, 4H), 6.80 - 6.75 (m, 2H), 4.56 (s, 4H), 2.52 (s, 3H).13C NMR (150 MHz, CDCI3): 5 162.7 (d, J = 243 Hz, 1C), 149.9, 145.7, 134.3 (d, J = 3 Hz, 1C), 128.6 (d, J= 7.5 Hz, 1C), 115.5 (d, J = 21 Hz, 1C), 111.0, 55.0, 14.9. HPLC- retention time, 1.43 min; Purity 100%. HRMS (ESI) m / z calculated for C22H19F2N3[M + H]+364.1620 found 364.1760.6-((4-(trifluoromethoxy) benzyl)amino)-1H-benzo[d]imidazole-2-thiol (Compound 22)

[0117] Yield: 16.6%. Rf= 0.30 (CH2CI2 / MeOH = 10 / 1).1H NMR (400 MHz, DMSO): 5 12.00 (s, 1H), 7.58 -7.49 (m, 2H), 7.29 (d, J = 8.2 Hz, 2H), 7.20 - 7.09 (m, 1 H), 6.57 (s, 1 H), 6.46 (dd, J = 8.4, 2.0 Hz, 1 H), 4.84 (s, 1H), 4.50 (s, 2H).13C NMR (100 MHz, DMSO): 5 147.9, 144.9, 138.3, 131.1, 121.5, 119.2 (q, J= 254.00 Hz, 1C),Docket No. 31196 / 25102 / PC111.2, 35.0. HPLC- retention time, 1.40 min; Purity 100%. HRMS (ESI) m / z calculated for C15H12F3N3OS [M + H]+340.0726 found 340.1580.2-methyl-N, N-bis(4-(trifluoromethyl)benzyl)benzo[d]oxazol-6-amine (Compound 24)

[0118] Yield: 32.7%.1H NMR (600 MHz, CDCI3): 57.59 (d, J = 7.8 Hz, 4H), 7.42 (d, J = 9.0 Hz, 1H), 7.38 (d, J= 8.4, 4H), 6.75 (d, 2.4 Hz, 1H), 6.67 (dd, J= 2.4, 2.4 Hz, 1H), 4.73 (s, 4H), 2.54 (s, 3H).13C NMR (150 MHz, CDCI3): 5 162.1, 152.6, 146.9, 142.3, 133.6, 129.8 (q, J = 96 Mhz, 10), 127.1, 125.9 (d, J = 4.5 MHz, 1 C), 125.1, 119.7, 110.8, 95.1, 55.3, 14.5. HPLC- retention time, 2.60 min; Purity 99%. HRMS (ESI) m / z calculated for C23H16F6N2O [M + H]+465.1396 found 465.1498.N-(4-fluorobenzyl)-2H-indazol-6-amine (Compound 26a)

[0119] Yield: 15%. Rf= 0.40 (CH2CI2 / MeOH = 10 / 1).1H NMR (600 MHz, DMSO): 5 12.29 (s, 1H), 7.73 (t, J = 1.2 Hz, 1H), 7.45 - 7.37 (m, 3H), 7.18 - 7.12 (m, 2H), 6.61 (dd, J= 9.0, 1.8 Hz, 1H), 6.50 (t, J = 6.0 Hz, 1H), 6.30 - 6.26 (m, 1H), 4.30 (d, J = 6.0 Hz, 2H).13C NMR (150 MHz, DMSO): 5 162.4 (d, J= 240 Hz, 10), 148.0, 142.4, 136.6 (d, J = 3 Hz, 10), 133.6, 129.4 (d, J = 7.5 Hz, 10), 121.0, 115.8, 115.6 (d, J = 21 Hz, 10), 115.4, 112.6, 88.2, 46.4. HPLC- retention time, 2.00 min; Purity 100%. HRMS (ESI) m / z calculated for C14H12FN3 [M + H]+242.1088 found 242.1219.N-(4-(trifluoromethoxy) benzyl)-2H-indazol-6-amine (Compound 26b)

[0120] Yield: 13.5%. Rf= 0.45 (C^CL / MeOH = 20 / 1).1H NMR (600 MHz, DMSO): 5 12.29 (s, 1H), 7.74 (s, 1 H), 7.70 (d, J = 7.8 Hz, 2H), 7.60 (d, J = 7.8 Hz, 2H), 6.63 (dd, J = 8.4, 1.8 Hz, 2H), 6.26 - 6.23 (m, 1 H), 4.44 (d, J= 4.8 Hz, 2H).13C NMR (151 MHz, DMSO): 5 147.8, 145.7, 142.4, 133.6, 128.1, 127.9 (q, J= 31.5 Hz, 10), 125.8 (q, J = 270 Hz, 10), 125.7 (q, J = 3 Hz, 10), 121.1, 115.9, 112.6, 88.3, 46.7. HPLC- retention time, 2.31 min; Purity 100%. HRMS (ESI) m / z calculated for C15H12F3N3 [M + H]+292.1056 found 292.1120.N-(4-(trifluoromethoxy) benzyl)-2H-indazol-6-amine (Compound 26c)

[0121] Yield: 43.3%. Rf= 0.45 (C^CL / MeOH = 20 / 1).1H NMR (600 MHz, CDCI3): 57.95 (s, 1H), 7.54 (d, J = 8.4 Hz, 1 H), 7.45 - 7.41 (m, 2H), 7.22 (d, J = 8.4 Hz, 2H), 6.66 (dd, J = 8.4, 1.8 Hz, 1 H), 6.57 (s, 1 H), 4.42 (s, 2H).13C NMR (150 MHz, CDCI3): 5 148.6, 147.9, 141.9, 137.0, 132.7, 128.9, 128.9, 122.1 (q, J = 250.5 Hz, 10), 121.8, 121.3, 116.0, 114.1, 89.2, 47.8. HPLC- retention time, 2.43 min; Purity 100%. HRMS (ESI) m / z calculated for C15H12F3N3O [M + H]+308.1005 found 308.0980.N, N-bis(4-fluorobenzyl)-2H-indazol-6-amine (Compound 27a)

[0122] Yield: 2%. Rf= 0.60 (C^CL / MeOH = 10 / 1).1H NMR (600 MHz, DMSO): 5 12.36 (s, 1H), 7.81 - 7.75 (m, 1H), 7.47 (d, J = 9.0 Hz, 1H), 7.34 - 7.28 (m, 4H), 7.19 - 7.12 (m, 4H), 6.74 (dd, J = 9.0, 2.4 Hz, 1H), 6.51 -6.45 (m, 1H), 4.73 (s, 4H).13C NMR (151 MHz, DMSO): 5 162.4 (d, J = 240 Hz, 10), 147.6, 142.2, 135.4 (d, J = 3 Hz, 10), 133.5, 129.0 (d, J = 9.0 Hz, 10), 121.3, 116.1, 115.8 (d, J = 21 Hz, 10), 110.8, 91.1, 54.5, 31.2. HPLC- retention time, 3.30 min; Purity 100%. HRMS (ESI) m / z calculated for C21H17F2N3[M + H]+350.1463 found 350.1500.Docket No. 31196 / 25102 / PCW-(4-(trifluoromethoxy) benzyl)-1H-indol-6-amine (Compound 29)

[0123] Yield: 23.0%. Rf= 0.25 (hexane / ethyl acetate = 4 / 1).1H NMR (600 MHz, DMSO-d6): 3 10.47 (s, 1H), 7.54 - 7.48 (m, 2H), 7.35 - 7.28 (m, 2H), 7.22 (d, J = 8.4 Hz, 1 H), 6.95 (dd, J = 3.0, 2.4 Hz, 1 H), 6.49 (dd, J = 8.4, 2.4 Hz, 1H), 6.39 (d, J = 2.4 Hz, 1H), 6.18 (ddd, J = 3.0, 2.4, 0.9 Hz, 1H), 6.00 (t, J = 6.0 Hz, 1H), 4.32 (d, J = 6.0 Hz, 2H).13C NMR (150 MHz, DMSO-d6): 6 147.4, 144.6, 140.9, 137.8, 129.3, 123.1 (q, J = 255.0 Hz, 1C), 122.2, 121.3, 120.7, 119.9, 109.6, 101.3, 93.2, 47.0. HPLC- retention time, 2.43 min; Purity 100%. HRMS (ESI) m / z calculated for C16H13F3N2O [M + H]+307.1053 found 307.1026.Synthesis of Compounds 33-34, 36, 38a-c, 41a-c, 42, and 57

[0124] Compounds 33-34 were synthesized following the method of Procedure E. Compound 33 is an intermediate in the route to Compound 34. Compounds 36, 38a-c, and 57 were synthesized following the method of Procedure F. The initial starting material in Procedure F is an intermediate in the method of Procedure E. Compounds 41a-c and 42 were synthesized following the method of Procedure G.Procedure E:

[0125] A variety of benzyl ethers were synthesized via a Williamson ether synthesis between suitably substituted benzyl bromides and commercially available 4-amino-3-nitrophenol to afford nitro intermediates.Docket No. 31196 / 25102 / PCSubsequent reduction of the nitro to the amine was accomplished using Zinc or Raney Nickel to afford diamines. The trifluoromethyl derivative 32b underwent HATU mediated coupling with glycolic acid to obtain amide 33 (Procedure E) or cyclization under neat conditions with formic acid to obtain benzimidazole 36 (Procedure F).Cyclization of 33 by exposure to acetic acid afforded ether derivative 34 (Procedure E). Diamines were subjected to cyclization with neat acetic acid to obtain benzimidazoles of type 38a-c.

[0126] Alternatively, commercially available 3,5-dinitrobenzoic acid was converted to its acid chloride by exposure to thionyl chloride and immediately reacted with commercially available 4-fluorobenzene under Friedel-Crafts conditions to afford the desired benzophenone. The dinitrophenyl intermediate was then reduced using Raney nickel to afford the diamine, followed by cyclization with suitably substituted acids to afford ketone derivatives of type 41a. Sodium borohydride reduction of 41a afforded alcohol 42 (Procedure G).W-(2-amino-4-((4-(trifluoromethyl) benzyl) oxy) phenyl)-2-hydroxyacetamide (Compound 33)

[0127] Yield: 29%. Rf= 0.40 (hexane / ethyl acetate = 30 / 1).1H NMR (600 MHz, MeOD) 57.66 (d, J= 8.1 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H), 7.05 (d, J = 8.6 Hz, 1 H), 6.52 (d, J = 2.7 Hz, 1 H), 6.39 (dd, J = 8.6, 2.8 Hz, 1 H), 5.13 (s, 2H), 4.15 (s, 2H). 13C NMR (100 MHz, MeOD): 5 172.9, 158.0, 143.5, 142.2, 127.3, 127.2, 125.0, 124.9, 124.9, 116.3, 104.6, 102.8, 68.6, 61.5. HPLC- retention time, 1.71 min; Purity 95%. HRMS (ESI) m / z calculated for C16H15F3N2O3[M + H]+341.1108 found 341.0668.(6-((4-(trifluoromethyl) benzyl) oxy)-1H-benzo[d]imidazol-2-yl) methanol (Compound 34)

[0128] Yield: 100%.1H NMR (600 MHz, MeOD) 57.67 (q, 1H), 7.44 (d, J= 8.7 Hz, H), 7.12 (d, J = 2.4 Hz, 1H), 6.97 (dd, J = 8.8, 2.4 Hz, 1H), 5.21 (s, 2H), 4.79 (s, 2H).13C NMR (151 MHz, MeOD) 5 156.6, 156.0, 143.7, 131.0, 130.8, 128.8, 126.6, 126.4, 126.4, 126.4, 126.3, 113.7, 70.8, 58.9. HPLC- retention time, 1.61 min; Purity 99%. HRMS (ESI) m / z calculated for C16H13F3N2O2 [M + H]* 323.1002 found 323.0591.6-((4-(trifluoromethyl) benzyl) oxy)-1H-benzo[d]imidazole (Compound 36)

[0129] Yield: 5%.1H NMR (600 MHz, CDCI3) 5 12.63 (s, 1H), 8.23 (s, 1H), 7.67 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 7.8 Hz, 2H), 7.56 (d, J= 7.8 Hz, 2H), 7.11 (s, 1H), 7.11 (d, J = 7.2 Hz, 1H), 5.15 (s, 2H).13C NMR (150 MHz, CDCI3) 5 155.5, 141.2, 140.9, 137.8, 133.4, 130.2,129.9, 127.4,125.5, 125.5, 125.5, 125.5, 125.1, 123.2, 116.6, 113.3, 99.3, 69.9. HPLC- retention time, 2.0 min; Purity 98%. HRMS (ESI) m / z calculated for C15H11F3N2O [M + H]+293.0896 found 293.0870.6-((4-fluorobenzyl)oxy)-2-methyl-1 H-benzo[d]imidazole (Compound 38a)

[0130] Yield: 14%. Rf= 0.40 (hexane / ethyl acetate = 30 / 1).1H NMR (600 MHz, CDCI3) 5 11.19 (s, 1H), 7.45 (d, J= 8.7, 1 H), 7.37 (q, J = 4.6 Hz, 2H), 7.09 (d, J = 2.1, 1 H), 7.02 (t, J = 8.7 Hz, 2H), 6.94 (dd, J = 2.2 Hz, 2.2Hz, 1H), 5.00 (s, 2H), 2.61 (s, 3H)13C NMR (150 MHz, CDCI3) 5 163.3, 161.7, 155.1, 151.6, 139.0, 133.9, 133.0 (d, J = 3.1 Hz, 1C), 129.4 (d, J = 8.5 Hz, 1C), 115.4 (t, J = 22.8 Hz, 1C), 112.1, 99.2, 70.3, 14.9. HPLC-retention time, 1.53 min; Purity 100%. HRMS (ESI) m / z calculated for C15H13FN2O [M + H]+257.1085 found 257.0318.Docket No. 31196 / 25102 / PC2-methyl-6-((4-(trifluoromethyl) benzyl) oxy)-1H-benzo[d]imidazole (Compound 38b)

[0131] Yield: 3.7%. Rf= 0.45 (hexane / ethyl acetate = 30 / 1).1H NMR (600 MHz, CDCI3) 58.18 (br.s, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.52 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 8.7 Hz, 1 H), 7.06 (d, J = 2.4 Hz, 1 H), 6.93 (dd, J = 8.7, 2.4 Hz, 1H), 5.10 (s, 2H), 2.58 (s, 3H).13C NMR (150 MHz, CDCI3) 5 154.9, 151.2, 141.3, 138.8, 133.6, 130.4, 130.1, 129.9, 129.7, 127.4, 125.5, 125.5, 125.0, 123.2, 115.2, 112.1, 99.2, 69.9 HPLC- retention time, 1.62 min; Purity 99%. HRMS (ESI) m / z calculated for C16H13F3N2O [M + H]+307.1053 found 307.1024.2-methyl-6-((4-(trifluoromethoxy)benzyl)oxy)-1 H-benzo[d]imidazole (Compound 38c)

[0132] Yield: 4.9%. Rf= 0.45 (hexane / ethyl acetate = 30 / 1).1H NMR (600 MHz, CDCI3) 5 10.21 (s, 1H), 7.43 (m, 3H), 7.20 (d, J = 8.3 Hz, 2H), 7.08 (d, J = 2.2 1 H), 6.93 (dd, J = 2.3 Hz, 2.4Hz, 1 H), 5.04 (s, 2H), 2.60 (s, 3H)13C NMR (150 MHz, CDCI3) 5 155.0, 151.3, 148.8 (d, J = 1.7 Hz), 138.8, 135.9, 133.6, 128.9, 121.3, 121.1, 119.6. 115.2. 112.1, 69.9, 14.8. HPLC- retention time, 1.7 min; Purity 100%. HRMS (ESI) m / z calculated for C16H13F3N2O2 [M + H]+323.1002 found 323.0975.(4-fluorophenyl) (2-(hydroxymethyl)-1H-benzo[d]imidazol-5-yl)methanone (Compound 41a)

[0133] Yield: 57%. Rf= 0.15 (CH2CI2 / MeOH = 10 / 1).1H NMR (600 MHz, MeOD): 58.01 (s, 1H), 7.90 - 7.84 (m, 2H), 7.75 (dd, J= 8.4, 1.2 Hz, 1H), 7.68 (d, J= 8.4 Hz, 1H), 7.29 (t, J= 8.4 Hz, 2H), 4.90 (s, 2H).13C NMR (150 MHz, MeOD): 5 195.8, 166.1 (d, J = 252.17 Hz, 1C), 158.2, 134.6 (d, J = 9.06 Hz, 1C), 132.4, 132.3, 131.7, 124.3, 117.8, 115.1, 114.9 (d, J = 22.65 Hz, 1C), 57.6. HPLC- retention time, 1.65 min; Purity 100%. HRMS (ESI) m / z calculated for C15H11FN2O2[M + H]+271.0877 found 271.0874.(4-fluorophenyl) (2-methyl-1H-benzo[d]imidazol-5-yl)methanone (Compound 41b)

[0134] Yield: 72%. Rf= 0.15 (CH2CI2 / MeOH = 10 / 1).1H NMR (600 MHz, CDCI3): 5 11.32 (s, 1H), 8.03 (s, 1H), 7.84 (dd, J= 8.4, 5.4 Hz, 2H), 7.72 (dd, J = 8.4, 1.2 Hz, 1H), 7.61 (d, J= 8.4 Hz, 1H), 7.14 (t, J= 8.4 Hz, 2H), 2.72 (s, 3H).13C NMR (150 MHz, CDCI3): 5 195.7, 166.1 (d, J = 253.68 Hz, 1C), 154.3, 138.2, 134.4, 132.6 (d, J = 9.06 Hz, 1C), 131.8, 124.9, 117.4, 115.5 (d, J = 22.65 Hz, 1C), 114.2, 15.1. HPLC- retention time, 1.45 min; Purity 98%. HRMS (ESI) m / z calculated for C15H11FN2O [M + H]+255.0928 found 255.0919.(1H-benzo[d]imidazol-5-yl) (4-fluorophenyl) methanone (Compound 41c)

[0135] Yield: 27%. Rf= 0.15 (CH2CI2 / MeOH = 10 / 1).1H NMR (600 MHz, MeOD): 58.37 (s, 1H), 8.07 - 8.04 (m, 1 H), 7.88 - 7.83 (m, 2H), 7.77 - 7.71 (m, 2H), 7.28 - 7.23 (m, 2H).13C NMR (150 MHz, MeOD): 5 195.6, 166.1 (d, J= 253.68 Hz), 144.0, 134.5 (d, J = 4.53 Hz), 132.4 (d, J = 9.06 Hz), 132.0, 124.5, 118.5, 115.1 (d, J = 22.65 Hz), 114.5. HPLC- retention time, 1.59 min; Purity 99%. HRMS (ESI) m / z calculated for C14H9FN2O [M + H]+241.0772 found 241.0757.(4-fluorophenyl) (2-(hydroxymethyl)-1H-benzo[d]imidazol-5-yl) methanol (Compound 42)

[0136] Yield: 79%. Rf= 0.10 (CH2CI2 / MeOH = 10 / 1).1H NMR (600 MHz, MeOD): 57.59 (d, J= 1.8 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1 H), 7.40 (dd, J = 8.6, 5.4 Hz, 2H), 7.23 (dd, J = 8.4, 1.6 Hz, 1 H), 7.07 - 7.00 (m, 2H), 5.90Docket No. 31196 / 25102 / PC(s, 1 H), 4.84 (s, 2H).13C NMR (150 MHz, MeOD) 5 162.8, 161.1, 155.4, 141.0 (d, J = 4.5 Hz, 1C), 139.2, 128.2 (d, J = 9.0 Hz, 2C), 121.4, 114.5 (d, J = 22.5 Hz, 2C), 114.4, 112.4, 75.1, 57.5. HPLC- retention time, 1.30 min; Purity 97%. HRMS (ESI) m / z calculated for C15H13FN2O2 [M + H]+273.1034 found 273.1001.6-(benzyloxy)-2-methyl-1H-benzo[d]imidazole (Compound 57)

[0137] Yield: 38%. Rf= 0.40 (hexane / ethyl acetate = 7 / 3).1H NMR (600 MHz, CDCI3) 58.19 (s, 1H), 7.42 (dd, J = 9.5, 7.7 Hz, 3H), 7.38 - 7.32 (m, 2H), 7.32 - 7.27 (m, 1 H), 7.08 (d, J = 2.4 Hz, 1 H), 6.94 (dd, J = 8.8, 2.4 Hz, 1H), 5.03 (s, 2H), 2.57 (s, 3H).13C NMR (151 MHz, CDCI3) 5 155.43, 151.12, 138.58, 137.24, 133.52, 128.66, 128.03, 127.64, 115.29, 112.41, 99.06, 70.93, 14.85. HPLC- retention time, 1.80 min; Purity 100%. HRMS (ESI) m / z calculated for C15H14N2O [M + H]+239.1179 found 239.1201.Synthesis of Compounds 49-50, 54, 59a-c, and 61 a-b

[0138] Compounds 49-50 were synthesized according to the method of Procedure H. Compound 54 was synthesized according to the method of Procedure I. Compounds 59a-c were synthesized according to the method of Procedure J. Compounds 61 a-b were synthesized according to the method of Procedure K. The starting compounds for Procedures J and K are synthesized via method of Procedure E.Procedure H:Docket No. 31196 / 25102 / PCProcedure K:

[0139] Commercially available 4-nitro-o-phenylenediamine was cyclized with acetic acid. The imidazole nitrogen was Boc protected, and the amine was accessed by hydrogenation using Palladium on carbon.Subsequent HATU mediated coupling with a suitably functionalized benzyl carboxylic acid afforded the amide analog, or reaction with benzyl isocyanate afforded the urea analog. Deprotection with TFA afforded the desired 1 / - / -benzo[d]imidazoles 49 and 50 (Procedure H).

[0140] Alternatively, commercially available 4-nitro-o-phenylenediamine was cyclized with ethyl isothiocyanatidocarbonate using DCC as a coupling reagent. Catalytic hydrogenation followed by N-alkylation with p-trifluoromethoxybenzyl bromide yielded carbamate 54 (Procedure I).

[0141] Alternatively, to 4-((4-(trifluoromethyl)benzyl)oxy)benzene-1,2-diamine (1.0 equiv, 1.06 mmol) in DMF (10 mL) and water (1.1 mL), was added the appropriate aromatic aldehyde (1.0 equiv). The reaction mixture was heated at 80 °C in open air for 24 hours. After completion, the mixture was cooled to room temperature, water was added and the solid was collected by filtration. The solid was washed with cold hexane and water and dried under vacuum to give the cyclized product (Procedure J).

[0142] Alternatively, to 4-((4-(trifluoromethyl)benzyl)oxy)benzene-1,2-diamine was added the appropriate aromatic carboxylic acid and HCI. The reaction was heated to 100°C for 12 hours, and the cyclized product was obtained (Procedure K).W-(2-methyl-1H-benzo[d]imidazol-6-yl)-2-(4-(trifluoromethoxy) phenyljacetamide (Compound 49)

[0143] Yield: 51%. Rf= 0.25 (CH2CI2 / MeOH = 10 / 1).1H NMR (600 MHz, MeOD): 57.91 (d, J= 1.8 Hz, 1H), 7.50 -7.46 (m, 2H), 7.42 (d, J= 8.4 Hz, 1H), 7.28 -7.22 (m, 3H), 3.75 (s, 2H), 2.55 (s, 3H).13C NMR (150 MHz, MeOD): 5 170.2, 152.2, 148.1, 137.6, 135.9, 134.9, 133.2, 130.5, 123.1 (q, J = 253.5 Hz, 1C), 120.7, 115.5, 114.2. 105.8, 42.3, 12.9. HPLC- retention time, 1.39 min; Purity 100%. HRMS (ESI) m / z calculated forC 17H 14F3N3O2[M + H]+350.1111 found 350.1137.1-benzyl-3-(2-methyl-1H-benzo[d]imidazol-6-yl) urea (Compound 50)

[0144] Compound 97.7%. Rf= 0.15 (CH2CI2 / MeOH = 10 / 1).1H NMR (600 MHz, MeOD): 57.69 (d, J= 1.8 Hz, 1 H), 7.39 (d, J = 8.4 Hz, 1 H), 7.37 - 7.31 (m, 4H), 7.25 (ddd, J = 6.6, 4.8, 2.4 Hz, 1 H), 7.07 (dd, J = 8.4, 1.8 Hz, 1H), 4.42 (s, 2H), 2.55 (s, 3H).13C NMR (150 MHz, MeOD): 5 157.3, 151.6, 139.7, 134.4, 128.1, 126.9, 126.7, 115.5. 104.8, 43.2, 12.9. HPLC- retention time, 1.26 min; Purity 100%. HRMS (ESI) m / z calculated for C16H16N4O [M + H]+281.1397 found 281.1368.Docket No. 31196 / 25102 / PCEthyl (6-((4-(trifluoromethoxy) benzyl)amino)-1H-benzo[d]imidazol-2-yl) carbamate (Compound 54)

[0145] Yield: 24%. Rf= 0.25 (hexane / ethyl acetate = 4 / 1).1H NMR (600 MHz, DMSO-d6): 5 11.24 (s, 2H), 7.54 - 7.47 (m, 2H), 7.33 - 7.28 (m, 2H), 7.08 (d, J = 8.4 Hz, 1 H), 6.52 (d, J = 2.4 Hz, 1 H), 6.47 (dd, J = 8.4, 2.4 Hz, 1H), 6.02 (s, 1H), 4.33 - 4.26 (m, 2H), 4.15 (q, J = 7.2 Hz, 2H), 1.24 (t, J= 7.2 Hz, 3H).13C NMR (150 MHz, DMSO-c / g) 5 147.5, 144.5, 140.5, 129.4, 121.4, 121.3, 119.7, 109.2, 61.2, 47.1, 15.0. HPLC- retention time, 1.42 min; Purity 99%. HRMS (ESI) m / z calculated for C18H17F3N4O3 [M + H]+395.1326 found 395.1333.2-(4-chlorophenyl)-6-((4-(trifluoromethyl)benzyl)oxy)-1H-benzo[d]imidazole (Compound 59a)

[0146] Yield: 1.5%. Rf=0.60 (Mobile phase hexane / ethyl acetate =2 / 1).1H NMR (400 MHz, CDCI3) 57.93 (d, J = 8.5 Hz, 2H), 7.64 (d, J= 8.1 Hz, 2H), 7.56 (d, J = 8.1 Hz, 2H), 7.44 (d, J= 8.6 Hz, 2H), 7.11 (s, 1H), 7.00 (dd, J = 8.8, 2.4 Hz, 1H), 5.16 (s, 2H).13C NMR (101 MHz, CDCI3) 5 160.62, 155.71, 150.56, 149.44, 141.28, 136.32, 130.10, 129.52, 128.33, 127.66, 127.55, 125.75, 125.72, 125.68, 121.92, 113.64, 69.98. HPLC- retention time, 1.97 min; Purity 100%. HRMS (ESI) m / z calculated for C21H14ClF3N2O [M + H]+403.0820 found 402.9989.2-(4-bromophenyl)-6-((4-(trifluoromethyl)benzyl)oxy)-1H-benzo[d]imidazole (Compound 59b)

[0147] Rf=0.60 (Mobile phase hexane / ethyl acetate =2 / 1)1H NMR1H NMR (400 MHz, DMSO-d6) 5 12.85 (s, 1 H), 8.22 - 7.95 (m, 2H), 7.87 - 7.63 (m, 6H), 7.61 - 7.00 (m, 2H), 6.95 (d, J = 8.3 Hz, 1 H), 5.29 (s, 2H).13C NMR (151 MHz, CDCI3) 513C NMR (151 MHz, CDCI3). 5 154.96, 149.68, 142.38, 138.61, 131.98, 129.49, 128.36, 128.15, 127.98, 127.00, 125.37- 125.35 (d, J= 2.0 Hz), 125.20, 123.39, 119.65, 113.34, 112.14, 95.97, 68.89. HPLC- retention time, 2.13 min; Purity 100%. HRMS (ESI) m / z calculated for C21H14BrF3N2O [M + H]+449.0294 found 448.9368.2-(pyridin-2-yl)-6-((4-(trifluoromethyl)benzyl)oxy)-1H-benzo[d]imidazole (Compound 59c)

[0148] Yield: 28.7%. Rf=0.60 (Mobile phase hexane / ethyl acetate =2 / 1) Tautomer A:1H NMR (400 MHz, DMSO) 5 12.97 (s, 1 H), 8.74 - 8.70 (m, 1 H), 8.27 (dt, J = 4.0, 1.1 Hz, 1 H), 8.02 - 7.97 (m, 1 H), 7.77 (dd, J = 8.5, 3.4 Hz, 4H), 7.61 (d, J = 8.8 Hz, 1 H), 7.52 - 7.49 (m, 1 H), 7.30 (d, J = 2.4 Hz, 1 H), 6.99 (dd, J = 8.7, 2.4 Hz, 1 H), 5.28 (s, 2H).13C NMR (100 MHz, DMSO) 5 155.21, 151.06, 149.38, 148.60, 144.55, 142.46, 138.75, 137.53, 135.54, 129.77, 128.00, 125.63, 124.57, 122.93, 121.24, 120.97, 119.99, 113.86, 112.51, 102.91, 96.16, 68.85. Tautomer B:1H NMR (400 MHz, DMSO) 5 12.94 (s, 1H,), 8.70 - 8.67 (m, 1H), 8.25 (dt, J = 4.0, 1.1 Hz, 1H), 7.97 - 7.93 (m, 1 H),7.71 (d, J = 8.0 Hz, 4H), 7.49 - 7.45 (m, 1 H), 7.43 (d, J = 8.8 Hz, 1 H), 7.08 (d, J = 2.3 Hz, 1 H), 6.95 (dd, J = 8.8, 2.5 Hz, 1H), 5.27 (s, 2H).13C NMR (100 MHz, DMSO) 5 154.18, 150.19, 149.30, 148.52, 144.55, 142.24, 137.48, 135.54, 127.97, 125.35, 124.38, 122.93, 121.24, 120.97, 119.99, 113.86, 112.38, 102.91, 96.16, 68.79. HPLC- retention time, 1.95 min; Purity 100%. HRMS (ESI) m / z calculated for C20H14F3N3O [M + H]+370.1162 found 370.1159.2-(3,5-difluorobenzyl)-6-((4-(trifluoromethyl)benzyl)oxy)-1H-benzo[d]imidazole (Compound 61a)

[0149] Yield: 29.0%. Rf=0.50 (Mobile phase hexane / ethyl acetate =2 / 1).1H NMR (400 MHz, CDCI3) 57.62 (d, J = 8.1 Hz, 2H), 7.54 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 8.8 Hz, 1 H), 7.03 (d, J = 2.4 Hz, 1 H), 6.96 (dd, J = 8.8, 2.4Docket No. 31196 / 25102 / PCHz, 1 H), 6.81 -6.72 (m, 2H), 6.66 (tt, J = 8.9, 2.3 Hz, 1H), 5.12 (s, 2H), 4.19 (s, 2H).13C NMR (101 MHz, CDCI3) 5 164.59 (d, J = 13.0 Hz), 162.11 (d, J= 12.9 Hz), 155.44, 151.50, 141.28, 139.93 (d, J = 9.2 Hz), 130.23 (d, J = 32.4 Hz), 127.52, 125.67 (q, J = 3.8 Hz), 122.86, 115.86, 113.10, 112.08 (d, J= 7.0 Hz), 111.90 (d, J = 7.0 Hz), 103.03 (t, J = 25.1 Hz), 99.37, 70.01, 35.42. HPLC- retention time, 0.69 min; Purity 100%. HRMS (ESI) m / z calculated for C22H15F5N2O [M + H]+419.1178 found 419.1243.2-(4-(trifluoromethoxy)benzyl)-6-((4-(trifluoromethyl)benzyl)oxy)-1H-benzo[d]imidazole (Compound 61b)

[0150] Yield: 2.68%. Rf=0.50 (Mobile phase hexane / ethyl acetate =2 / 1).1H NMR (400 MHz, CDCI3) 57.60 (d, J = 8.1 Hz, 2H), 7.52 (d, J = 8.0 Hz, 2H), 7.40 (s, 1H), 7.24 (d, J= 1.8 Hz, 2H), 7.17 - 7.08 (m, 2H), 7.01 (s, 1H), 6.92 (dd, J = 8.7, 2.4 Hz, 1H), 5.11 (s, 2H), 4.18 (s, 2H).13C NMR (101 MHz, CDCI3) 5 155.23, 148.58, 141.39, 135.13, 130.44, 130.37, 130.05, 127.50, 125.72-125.61 (q, J= 3.7 Hz), 125.57, 122.87, 121.83, 121.65, 119.27, 77.48, 77.16, 76.84, 70.02, 35.32. HPLC- retention time, 1.90 min; Purity 100%. HRMS (ESI) m / z calculated for C23H16F6N2O2 [M + H]+467.1189 found 467.1206.Example 2: Biological Studies

[0151] Compounds disclosed herein were evaluated for biological activity using several methods.Cell Culture and Treatment

[0152] CLN3 IPSCs were obtained from the New York Stem Cell Foundation IPS Core Facility (NYSCF, New York City, NY, USA), derived from a patient with a heterogeneous CLN3 gene mutation. The IPSCs were cultured on Matrigel-coated 35 mm or 6-well culture plates using mTeSR™ Plus medium, following the protocol described in our previous publication.38The control IPSC line CS2BFUIALS-n2-GE14, derived from a 44-year-old male, was established by, and acquired from, the Cedars-Sinai Biomanufacturing Center, CA, USA.Undifferentiated IPSC colonies were cultured on LDEV-free Matrigel Growth Factor Reduced (GFR) Basement Membrane Matrix (Corning, MA, USA) and maintained in mTeSRTM Plus medium (StemCell Technologies, MA, USA). Upon reaching confluence after 4 days, the undifferentiated IPSCs were dissociated using Accutase to obtain single-cell suspensions in fresh medium. The cells were then centrifuged, resuspended in fresh medium, and seeded at a density of 2.5 X 105cells / mL on Matrigel-coated plates. Neural induction medium (NIM) was used to maintain the culture for 4-6 days, with daily medium changes, to promote the generation of neural stem cells (NSCs). On day 4, the confluent NSCs were converted to neural progenitor cells (NPCs) by dissociation with Accutase and subsequent plating in neurodifferentiation medium (NDM) supplemented with GDNF and BDNF each at 10 pig / mL After dissociation, cells were collected in fresh medium, centrifuged, resuspended, and seeded at a density of 2.5 X 105cells / mL on Poly-D-lysine (PDL)- and Laminin / Matrigel-coated plates. The NSCs were maintained for 6 days to allow differentiation into NPCs, which were then used for further experiments. Cells were seeded into 12-, 24-, or 96-well plates at a density of 2.5 X 105cells / mL and incubated overnight before treatment. Small molecules were dissolved in DMSO, and treatments were performed using NDM. The final DMSO concentration in the cell cultures was kept below 0.05% for both the treatment and control groups.Docket No. 31196 / 25102 / PCImmunocytochemistry for morphological characterization

[0153] CLN3 NPC cells were seeded at a density of 5 x 105cells / mL onto 8-well slide chambers and incubated overnight. The cells were examined for appropriate morphological appearance; only those with satisfactory morphology were included in subsequent procedures. Afterward, the cells were washed once with PBS (pH 7.4) and fixed with 70% ethanol and 100% methanol, each for 10 minutes at room temperature. The cells were then washed three times with PBS for 5 minutes each, followed by permeabilization with 0.3% Triton X-100 in PBS for 20 minutes. After washing once more with PBS, the cells were blocked with 5% BSA containing 0.025% Triton X-100 for 30 minutes at room temperature. Subsequently, the cells were incubated overnight with primary antibodies in a shaker at 4°C. After the incubation, the cells were washed three times with PBS for 10 minutes each. Next, the cells were incubated with FITC-conjugated recombinant mouse secondary antibody (1:200 dilution) overnight at 4°C with shaking. After a final series of three PBS washes, the slides were mounted using Vectashield mounting medium with DAPI. Images of the stained cells were captured using a Zeiss Axioscan 7 Whole Slide Imaging System and can be seen in FIGs. 1A-1C.Cell Viability Assay

[0154] Cell viability of CLN3 NPCs was assessed using the CellTiter 96 AQueous MTS reagent (Thermo Fisher Scientific), following the manufacturer's instructions. CLN3 NPCs were seeded at a density of 2.5 X 105cells / mL in 96-well plates and incubated overnight. The cells were then treated with small molecules at concentrations of 10 piM or 0.1 piM, 1 piM, 3 piM, 10 piM, 100 piM in triplicate, and incubated at 37 °C with 5% CO2. A DMSO vehicle-treated control group was maintained simultaneously. Following treatment, MTS reagent was added to the wells, and the cells were incubated to allow for formazan product formation. Absorbance was measured at 490 nm using a multi-mode microplate reader (Agilent BioTek Synergy LX, Vermont, USA). Data were expressed as the percentage of viable cells in the experimental conditions relative to the vehicle-treated control.

[0155] To fully assign a SAR, the compounds of the disclosure were separated into three classes: I) benzimidazole alcohol analogues (Table 1); ii) benzimidazole benzyl ether analogs (Table 2); ill) heterocyclic analogues (Table 3); iv) ether analogues (Table 4); v) hybrid analogues (Table 5). As brain penetration is a critical property for the treatment of CLN3 disease, the central nervous system (CNS) muitiparameter optimization (MPO) score was employed as an in silica predictor of blood-brain-barrier (BBB) penetration. Compounds were designed to possess an MPO score of four or greater which is predictive of BBB penetration. Compounds were initially screened at a single concentration of 10 piM in CLN3 patient iPSC-derived NPCs over 24 hours using an MTS assay with ceil viability normalized to 100% control (FIG. 2). The parent compound, Flupirtine, and a previously reported compound, L1, were included as controls.

[0156] The benzimidazole alcohol analogues were first studied. Compound L1 showed protective effect at 10 μM concentration in agreement with previously reported values, posing a 33% protective effect, compared with the Flupirtine parent (13%). Cyclization of the diamino moiety of L1 did not ablate activity. All the cyclized (1 / 7-Docket No. 31196 / 25102 / PCbenzo[c / |imidazol-2-yl) methanol analogues (Table 1) displayed protective effects similar to L1 and superior to Flupirtine. The cyclized analog of Retigabine (9a) was equipotent with Flupirtine within standard deviation (35% protective effect). The cyclized analogue of L1 (9b) also retained protective effect at 32% cell viability promotion. Without wishing to be bound by any particular theory, the OCF3 analogue (9c) and SCF3 analogue (9d) conferred greater protective effect (48% for both), suggesting no role for the higher lipophilicity of the SCF3 group over the OCF3 group.Table 1:

[0157] The benzimidazole benzyl ether analogs (Table 2) afforded no appreciable increase in protective effect for fluorine or trifluoromethoxy substituents within standard deviation (compare 9a (35%) v 10a (34%) and 9c (48%) v 10c (57%)). Both were more active than the Flupirtine hit compound. However, introduction of the benzyl ether motif reduced MPO scores, particularly in the case of 10c, where a substantial drop to 3.0 was calculated.Table 2:

[0158] Heterocyclic analogues were then studied (Table 3). The benzothiazole analogue of Retigabine (14a) afforded cell viability protection equipotent with the Flupirtine parent, but lower than the benzimidazole scaffold. Addition of a methyl group to the 2-position of the benzothiazole (14b) ablated protective effect with a 2% reduction in cell viability for fluoro-substituted benzylamines. No effect on cell viability was observed with trifluoromethyl substituted benzylamines (14d). A series of N-alkylated fluoro- (15a-b) and trifluoromethyl (15c) benzylamine analogues provided no increase in protective effect over L1 irrespective of the 2-position substituent, suggesting the potential importance for the amine hydrogen to form polar contacts in active derivatives. A positional switch of the sulfur atom with the nitrogen atom (17) provided similar activity equipotent with Flupirtine. 2-methylbenzimidazoles with trifluormethylbenzylamine substitution (19b) and trifluoromethoxybenzylamine substitution (19c) provided equipotent protective effect with their methylene alcohol analogues 9b and 9c, but reduced activity compared to benzyl ether 10c. N-alkylation with fluorobenzylamine (20) afforded no effect on activity. Installation of a thiol at the 2-position of benzimidazole analogue 22 yielded a compound with modest toxicity (5% reduction of cell viability). Benzoxazole 24, possessed protective effects (24%) equipotent with Flupirtine and greater than 15c. Benzimidazoles with 2-methylene alcohol (Table 1) or 2-Docket No. 31196 / 25102 / PCbenzylmethyelene ether substituents (Table 2) afforded greater protective effects than 2-hydrogen or 2-methyl substituted benzimidazoles, benzothiazoles, or benzoxazoles.

[0159] Indole and indazole bicyclic heterocycles were next investigated. Indole 11, albeit possessing a positional isomer of the 4-SCF3-benzylamine, was less active than both L1 and Flupirtine within experimental error. Indazoles (26a-c) provided protection of cell viability that was not significantly greater than the Flupirtine parent compound, with 9%, 18%, and 16% cell viability protection respectively. N-alkylation with a 4-flourobenzylamine (27a) resulted in a compound with the same protective effect as the non-alkylated parent (26a). Indole 29, the direct isostere of indazole 26c, afforded no effect on cell viability.Table 3:

[0160] The Western ether analogues were then investigated (Table 4). The amide intermediate 33 showed no appreciable protective activity. The 4-trifluoromethyl benzyl ether 34, a direct bioisostere of 9b, conferred a reduced protective effect (7% v 32% respectively) which was equipotent to the benzimidazole unsubstituted 2-position analogue 36. The 2-methylbenzimidazole scaffold provided access to highly active compounds when combined with the benzyl ether bioisosteres. Fluoro-substituted derivative 38a afforded a 37% increase in cell viability at 10 piM. Trifluoromethyl derivative 38b, a direct bioisostere for benzylamine 19b, provided a much greater increase in cell viability of 74% compared with 24% respectively, the most potent compound identified. The trifluoromethoxy substituent (38c), a direct bioisostere of 19c, afforded cell viability protection of 36% versus 32%, respectively.Docket No. 31196 / 25102 / PCTable 4:

[0161] Finally, the hybrid analogues were studied (Table 5). Incorporation of a photoactivatable benzophenone moiety onto the 2-methylene alcohol benzimidazole scaffold (41a) ablated activity. Incorporation of the benzophenone into the 2-methyl benzimidazole scaffold (41b) reduced activity over the respective benzyl ether analogue 38a, 10% v 37% protective effect. Incorporation into the unsubstituted benzimidazole (41c) also ablated activity. Reduction of the ketone of 41a afforded inactive alcohol compound 42, which showed no protective effect. An amide-containing chain (49), an analogue of 38c, was inactive within experimental error. The inclusion of a urea side chain also ablated protective activity. The direct cyclized derivate of Retigabine (54) also proved to be inactive.Table 5:

[0162] A selection of compounds, including those with less activity than Flupirtine and L1 at 10 pM, to ensure that single concentration screening was not identifying false negatives, were taken forward for a 5-point doseresponse study (FIGs. 3A and 3B).

[0163] In the dose-response studies Flupirtine provided a maximum 9% protection of cell viability with a flat dose-response (Table 6). Linear compound L1, as expected, provided an improved Emax of 16% at 100 pM. Within the 2-substituted methylene alcohol benzimidazoles, compound 9a achieved Emax at the lowest concentration tested (0.1 pM) but only afforded 13% protection. Compounds 9b and 9c afforded similar Emaxof 20% and 31% respectively at 10 pM. Compound 9d afforded 15% protection at 3 pM. The 2-substituted methylenebenzyl ether benzimidazole 10a achieved an EmaxOf 26% at 100 pM concentration, while 10c possessed an Emaxof 20% at 0.1 pM, but activity declined at higher concentrations. Highlighting the greater activity of the alcohol over the ether. Compounds 33, 36, 41 b-c, 42, 49 and 50 had no effect up to 10 pM. AsDocket No. 31196 / 25102 / PCdelivering 100 pM of compound into the brain is unfeasible, all these low activity compounds were not taken further. Compound 33 began to show toxicity at 100 pM. The 2-methyl substituted benzimidazole 38b achieved an Emax of 74% at 10 pM concentration.Table 6:Autophagy Detection Assay

[0164] CLN3 NPC cells were seeded at a density of 2.5 x 105cells / mL onto 8-well slide chambers and incubated overnight. The cells were then treated with small molecules as described earlier. Autophagic induction was assessed using the Cyto-ID Autophagy Detection Kit. Cyto-ID is a dye that selectively labels accumulated autophagic vacuoles and monitors autophagic flux in lysosomally inhibited live cells. In addition to the small molecule treatment, cells were also treated with a mixture of 500 nM rapamycin and 10 pM chloroquine, included in the kit, as positive controls. All experiments were conducted following the manufacturer's protocol. Fluorescent images were captured using a Zeiss Axioscan 7 Whole Slide Imaging System. The induction of autophagy was evaluated by measuring the intensity of green fluorescence in the cytosol.

[0165] Significant autophagy dysfunction was seen in CLN3 patient-derived NPCs compared to healthy controls, indicating recapitulation of the phenotype (FIGs. 4A and 4B). An increase in green fluorescence intensity, indicating the activation of the autophagy pathway following treatment with 10 pM of L1, 9c, 9d, and 10a but not Flupirtine (FIG.4A). As expected, the positive control combination of chloroquine (autophagy inhibitor) and rapamycin (autophagy inducer) significantly increased autophagic flux. Quantification of these images (FIG.4B) revealed that L1, the two 2-methylene alcohol substituted benzimidazoles 9c and 9d, and 2-methyelenebenzyl ether benzimidazole, 10a, revealed a significant activation of autophagy that matched the observed compound ranking of neuroprotective effect by Emax; 9c > 9d = 10a.Western Blotting Analysis

[0166] CLN3 NPCs were treated with selected small molecules at a concentration of 10 pM for 24 hours. Following the treatment, cells were washed three times with PBS, and cell lysates were harvested using a cell scraper with RIPA lysis buffer. The lysates were centrifuged at low speed (1000xg), and the pellet was resuspended in RIPA buffer containing a 1X Halt Protease Inhibitor Cocktail and incubated on ice for 30 minutes. The lysates were sonicated on ice and subjected to centrifugation at 12,000 rpm for 20 minutes at 4°C. TheDocket No. 31196 / 25102 / PCsupernatant was collected, and protein concentration was determined using the BCA protein assay. Equal amounts of protein (30 pg) were separated by SDS-PAGE and transferred onto nitrocellulose membranes using the iBlot2 Dry Transfer System (Thermo Fisher Scientific, MA, USA). Membranes were blocked with 5% skim milk in TBST for 1 hour, followed by overnight incubation with primary antibodies in 2% BSA at 4°C with gentle shaking. After washing three times with TBST, the membranes were incubated with a secondary antibody (1:5000) in 5% skim milk / TBST for 1 hour at room temperature. Protein bands were visualized using an ECL detection system (Licor), and band intensities were quantified using Imaged 1,54f software (NIH, USA). Protein levels were normalized to GAPDH.Rescue of SCMAS Accumulation

[0167] The accumulation of SCMAS has been implicated in disrupting a variety of cellular processes including apoptosis, autophagy, and neuroinflammation in CLN3 disease. Non-CLN3 disease NPCs were used as control and all treatment experiments were normalized to a relative expression of 1. CLN3 patient-derived NPCs showed significant accumulation of SCMAS, confirming robust recapitulation of CLN3 phenotype. Treatment of CLN3 patient-derived NPCs with Flupirtine, 9b-c, and 10a at 10 piM concentration for 24 hours all showed a trend to rescue SCMAS accumulation. Treatment with the compound L1 significantly reduced SCMAS accumulation. Compound 9b effectively rescued SCMAS accumulation to healthy control levels, countering accumulation in the CLN3 NPCs. Compound 38b significantly rescued SCMAS accumulation reducing levels below that of health control NPCs. This data is depicted in FIG. 5.Kv7.2 / 7.3 Potassium Channel Assay

[0168] This assay was performed by Eurofins using the ICCUS00 Kv7.2 / Kv7.3 Human Potassium Ion Channel Cell Based Manual Patch Clamp Assay. The amplitude of the Kv7.2 / Kv7.3 peak outward current was calculated by measuring the current on stepping to -30mV. The current was measured before and after each compound addition. Individual cell results were normalized to their respective vehicle control and the results were averaged. The pulse protocol involved stepping from a holding potential of -80 mV to -30 mV for 1 s to evoke the peak outward K+current prior to returning to the holding potential. This sequence was repeated with an inter-pulse interval of 20 s. The voltage protocol was applied throughout the experiment starting prior to drug (Control) and after addition of test compound. Evoked peak outward current amplitudes were continuously monitored throughout the experiment. Each compound was applied to the cell for five (5) minutes. The Kv7.2 / Kv7.3 experiments were performed at room temperature (approximately 22 °C).

[0169] At 1 μM concentration, L1 showed agonism of Kv7.2 / 7.3 equipotent with Retigabine parent (normalized to vehicle control at 100%). However, compound 9b possessed significantly less activity at the Kv7.2 / 7.3 channel with no overall effect of activation. At 10 μM concentration, Retigabine, as expected, elicited 340% activation of the Kv7.2 / 7.3 channel, while L1 showed significantly lower activity with 246% activation. Benzoimidazole compound 9d elicited significantly less effect at the Kv7.2 / 7.3 channel, effectively showing no activation effectDocket No. 31196 / 25102 / PC(103%). Thus, activity at the primary target of the Retigabine and Flupirtine parent compounds has been eliminated in the benzoimidazole scaffold. The results are shown in FIGs. 6A and 6B.In Vitro Pharmacokinetic Studies

[0170] The in vitro metabolic stability of compounds was determined using human liver S9 fraction (XenoTech, LLC, Lenexa, KS, USA). Briefly compounds were incubated at 1 M in a 100 L mixture containing S9 fractions at 1 mg / mL protein concentration, NADPH (1 mM), saccharolactone (5 mM), uridine 5'-diphospho-glucuronic acid (UDPGA) (1 mM), and 3'-phosphoadenosin-5'-phosphosulphate (PAPS) (0.1 M) in PBS (100 mM, pH 7.4) at 37 °C. For each time point in the range of 0-90 min, reactions were quenched by adding 300 uL of ACN, followed by centrifugation at 15,000 x g for 15 min. Supernatants were then analyzed by LC-MS / MS. Heat-inactivated S9 fractions were incubated at the same conditions and used as negative controls. Hydroxycoumarin (7-HC) metabolites (7-HC-glucuronide and 7-HC-sulfate) formations, and the testosterone metabolite (6p-hydroxytestosterone) formations were used as positive controls for phase I and phase II metabolism.

[0171] Both compounds 9b and 38b possessed favorable in vitro metabolic stability with >80% and 76% remaining by 90 min of incubation respectively. Compound 38b showed a greater half-life than 9b with 224 v 193 minutes, respectively. Both compounds possessed similar elimination rate constant (K), in vitro clearance (CLint) into in vivo hepatic CLint, hepatic CL (CLH), and extraction ratio (ER). Overall, both compounds are considered metabolically stable, with ER of approximately 30% and suitable for in vivo pharmacokinetic profiling. The data can be seen in Table 7.Table 7:In Vivo Pharmacokinetic Studies

[0172] All animal procedures were performed in the Alnouti lab at UNMC according to the protocol (18-129-11-FC) approved by the IACUC of the University of Nebraska Medical Center. Male Balb / c mice (age 7-8 weeks) were purchased from Jackson Laboratory (Maine, USA). The compounds were freshly dissolved in a vehicle composed of DMSO, PEG400, PG EtOH, Cremophore, and PBS (2:20:10:10:5:53%) at 1 mg / mL for P. O. and 0.25 mg / mL for I. V. administrations. The oral dose was 10 mg / kg, and the intravenous dose was 1 mg / kg. Blood samples were collected from the facial vein by puncturing the skin using sterile 0.5 mm goldenrod animal lancets. The drops of freely flowing blood were collected in EDTA-containing tubes. Bleeding was stopped after collectingDocket No. 31196 / 25102 / PC~50 pL of blood by pressing the vein with a cotton ball. Blood was collected at various time points (0-48 h) postadministration, and the concentrations of each compound were measured using LC-MS / MS analysis.

[0173] For compound 9b, an ultra-performance liquid chromatography-tandem mass spectrometry (LC-MS / MS) system consisting of a 4000 Q-TRAP® triple quadrupole / linear ion trap hybrid mass spectrometer equipped with an electrospray ionization (ESI) source (Applied Biosystems, Foster City, CA) coupled with a Waters ACQUITY ultra-performance liquid chromatography (UPLC) system (Waters, Milford, MA) was used to perform the sample analyses. Data was processed using Analyst 1.7.3 software (Applied Biosystems, Foster City, CA). ACQUITY UPLC® BEH Shield RP18 Column (2.1x100mm, 1.7pm; Waters) was used for chromatographic separation of samples. The liquid chromatography conditions consisted of 0.1 % formic acid (55%) & methanol (45%) at a flow rate = 0.2 mL / min. Plasma samples were prepared by mixing 50 pL of the plasma sample with 150 pL acetonitrile, vortexed, and centrifuged at 17,000 x g for 15 min. Then 60 pL of supernatant was mixed with 30 pL of water and added to 10 pL of IS (DTG-d35 ng / mL DRV 5 ng / mL) before LCMS / MS injections. For compound 32b, the LC-MS / MS system was comprised of a Waters ACQUITY UPLC system coupled to a Waters Xevo TQ-XS triple quadrupole mass spectrometer (Waters, Milford, MA) with electrospray ionization (ESI) source. Data was processed using Masslynx 4.2 software (Waters, Milford, MA). Chromatographic separation was achieved using mobile phases 0.1% FA in water (50%) & MeOH (50%) at flow rate = 0.2 mL / min. ACQUITY UPLC® BEH Shield RP18 Column (2.1 x 50 mm, 1.7 m; Waters) equipped with Guard Column (VanGuardTM BEH C18 1.7 pm, Waters) was used at 25°C. Plasma samples were processed by spiking with 5 pL (20-X) internal standard (IS) (Rilpivirine at 20 pg / ml,) and extracted via protein precipitation with 300 pL acetonitrile and centrifuged at 16,000 x g for 10 min. Then, sample solvent composition of 100 pL of the supernatant was done by adding 50 pL H2O before LC-MS / MS injections.

[0174] Mice were split into two sets for each experiment, sacrificed at 6h and 48h after administering compound for tissue (brain, liver, kidney, lungs, and heart) collection. For compound 9b, tissue samples were homogenized in 4 volumes (w / v) of 80% methanol for compound 9b and 4 volumes (w / v) deionized water for compound 38b, then 100 pL homogenates were extracted before LC-MS / MS analysis. PK parameters were calculated using noncompartmental analysis of plasma concentration vs. time profiles using Phoenix WinNonlin V8.2 software.

[0175] Statistical analysis was conducted with Prism 10, using the indicated tests and p values. Both compounds 9b and 38b possessed a desirable 'drug-like' PK profile. The PK parameters of compound 9b after a single IV dose were determined as area under the curve (AUCo-~) = 482.43 ng.h / mL, elimination half-life (to.5) = 5.43 h, clearance = 3.7 L / h / kg, volume of distribution (Vss) = 4.0 L / kg, and mean residence time (MRT) = 1.1 h. After single P. O. administration, a maximum plasma concentration (Cmax) of 1793.4 ng / mL was observed after 0.5 h (Tmax) of dose administration, AUCo-~ was 2728.0 ng.h / mL, and MRT was 1.9 h.

[0176] The PK parameters of compound 38b after single IV dose were determined as area under the curve (AUCo-~) = 3,803.3 ng.h / mL, elimination half-life (to.5) = 6.04 h, clearance = 0.26 L / h / kg, volume of distributionDocket No. 31196 / 25102 / PC(Vss) = 0.41 L / kg, and mean residence time (MRT) = 1.54 h. After single P. O. administration, maximum plasma concentration (Cmax) of 5892 ng / mL was observed after 0.25 h (Tmax) of dose administration, AUCo-~ was 13,244.5 ng.h / mL, and MRT was 4.04 h.

[0177] Both compounds possessed increased half-life from 1.6 hours with L1 to 5.4 and 6.0 hours with IV dosage and 3.6 and 6.7 hours with oral dosage with compounds 9b and 38b respectively. Both compounds also showed good bioavailability, 57% for 9b and 35% for 38b at 10 mg / kg oral dosage. The data is summarized in Table 8.Table 8:

[0178] Compounds 9b and 38b were next assessed for tissue distribution. Mice were split into two sets, which were sacrificed at 6h and 48 h for 9b or 4h and 72h for 38b after PC and IV administration separately for tissue (brain, liver, kidneys, lungs, and heart) collection. Both compounds possess relatively high brain penetration with tissue / plasma ratio of 3.5 ± 0.2 for 9b and 3.2 ±0.5 for 38b after oral administration and 5.6 ± 0.33 for 9b and 4.5 ±0.6 for 38b after IV administration. Data are shown in Table 9.Docket No. 31196 / 25102 / PCTable 9:1Tissue concentrations are reported as Mean ± SEM (n=5).2Below limit of quantification.

Claims

Docket No. 31196 / 25102 / PCWhat is claimed is:

1. A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (I):whereinring A is a 5-membered heteroaryl moiety comprising 1 or 2 ring heteroatoms each independently selected from 0, N, and S;R1is H, halo, Ci-ehaloalkyl, -O-Ci-ehaloalkyl, or -S-Ci-ehaloalkyl;L is -Ci-3alkylene-0-, -Ci-salkylene-NR3-, -Ci-3alkylene-C(0)NH-, -Ci-3alkylene-NHC(0)NH-, -C(0)-, or -CH(OH)-;R2is H, -Ci-3alkyl, SH, -Ci-salkylene-OH, -NHC(0)0-Ci-3alkyl, -Co-aalkylene-Ce-ioaryl, -Co-3alkylene-(5-6 membered heteroaryl) wherein the heteroaryl comprises 1 or 2 heteroatoms each independently selected from 0, N, and S, or -Co-salkylene-O-Co-salkylene-Ce-ioaryl, and in each instance the aryl is substituted with 0, 1, or 2 substituents selected from halo and -O-Ci-shaloalkyl; andR3is H or -Co-salkylene-Ce-ioaryl, and the aryl is substituted with 1 substituent selected from halo and -Ci-3haloalkyl.

2. The compound or salt of claim 1, wherein ring A is a 5-membered heteroaryl moiety comprising 1 ring N heteroatom.

3. The compound or salt of claim 1 or 2, wherein ring A is a 5-membered heteroaryl moiety comprising 2 ring N heteroatoms.

4. The compound or salt of claim 1 or 2, wherein ring A is a 5-membered heteroaryl moiety comprising 1 ring N heteroatom and 1 ring S heteroatom.

5. The compound or salt of claim 1 or 2, wherein ring A is a 5-membered heteroaryl moiety comprising 1 ring N heteroatom and 1 ring 0 heteroatom.

6. The compound or salt of claim 1 or 2, wherein ring A is pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, or oxazolyl.Docket No. 31196 / 25102 / PCThe compound or salt of claim 1 or 2, wherein ring8. The compound or salt of any one of claims 1 to 7, wherein R2is H, -C1-3alkyl, or -C1-3alkylene-OH.

9. The compound or salt of any one of claims 1 to 8, wherein R2is H.

10. The compound or salt of any one of claims 1 to 8, wherein R2is -C1-3alkyl.

11. The compound or salt of claim 10, wherein R2is CH3.

12. The compound or salt of any one of claims 1 to 8, wherein R2is -C1-3alkylene-OH.

13. The compound or salt of any one of claims 1 to 7, wherein R2is CH2-OH.

14. The compound or salt of any one of claims 1 to 7, wherein R2is H, SH, CH3, CH2-OH, -NHC(O)O-CH2CH3, pyridyl, phenyl substituted with Cl or Br, -CH2-phenyl substituted with 2 F, -CF -phenyl substituted with OCF3, or -CH2-O-CH2-phenyl.

15. The compound or salt of claim 14, wherein R2is SH.

16. The compound or salt of claim 14, wherein R2is -NHC(O)O-CH2CH3.The compound or salt of claim 14, wherein R2isThe compound or salt of claim 14, wherein19. The compound or salt of claim 14, wherein R2is20. The compound or salt of claim 14, wherein R2is -CH2-O-CH2-phenyl.

21. The compound or salt of any one of claims 1 to 20, wherein R1is H.

22. The compound or salt of any one of claims 1 to 20, wherein R1is halo, C1-6haloalkyl, -O-C1-6haloalkyl, or -S-C1-6haloalkyl.

23. The compound or salt of claim 22, wherein R1is halo, C1-6haloalkyl, or -O-C1-6haloalkyl.

24. The compound or salt of claim 22, wherein R1is F, CF3, or OCF3.Docket No. 31196 / 25102 / PC25. The compound or salt of any one of claims 22 to 24, wherein R1is halo.

26. The compound or salt of claim 25, wherein R1is F.

27. The compound or salt of any one of claims 22 to 24, wherein R1is C1-6haloalkyl.

28. The compound or salt of claim 27, wherein R1is CF3.

29. The compound or salt of any one of claims 22 to 24, wherein R1is -O-C1-6haloalkyl.

30. The compound or salt of claim 29, wherein R1is OCF3.

31. The compound or salt of claim 22, wherein R1is -S-C1-6haloalkyl.

32. The compound or salt of claim 31, wherein R1is SCF3.

33. The compound or salt of any one of claims 1 to 32, wherein L is -C1-3alkylene-O- or -C1-3alkylene-NR3-.

34. The compound or salt of claim 33, wherein L is -C1-3alkylene-O-.

35. The compound or salt of claim 33, wherein L is -C1-3alkylene-NR3-.

36. The compound or salt of claim 35, wherein R3is H.

37. The compound or salt of claim 35, wherein R3is -C0-3alkylene-C6-10aryl and the aryl is substituted with 1 substituent selected from halo and -C1-3haloalkyl.

38. The compound or salt of claim 37, wherein R3is -C1alkylene-C6aryl and the aryl is substituted with 1 substituent selected from halo and -C1-3haloalkyl.

39. The compound or salt of claim 37 or 38, wherein R3is -C1-3alkylene-C6-10aryl and the aryl is substituted with 1 halo substituent.

40. The compound or salt of claim 39, wherein R3is F,41. The compound or salt of claim 37 or 38, wherein R3is -C1alkylene-C6-10aryl and the aryl is substituted with 1 -C1-3haloalkyl substituent.

42. The compound or salt of claim 41, wherein R3is.

43. The compound or salt of any one of claims 1 to 32, wherein L is -C1-3alkylene-C(O)NH-.

44. The compound or salt of claim 43, wherein L is -CH2-C(O)NH-.

45. The compound or salt of any one of claims 1 to 32, wherein L is -C1-3alkylene-NHC(O)NH-.

46. The compound or salt of claim 45, wherein L is -CH2-NHC(O)NH-.

47. The compound or salt of any one of claims 1 to 32, wherein L is -C(O).Docket No. 31196 / 25102 / PC48. The compound or salt of any one of claims 1 to 32, wherein L is -CH(OH)-.

49. The compound or salt of claim 1, having a structure selected from Formula (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), and (X):

50. The compound or salt of claim 49, having a structure selected from Formula (II) and (III).

51. A compound having a structure shown in Table A, or a pharmaceutically acceptable salt thereof.

52. A pharmaceutical composition comprising the compound or salt of any one of claims 1 to 49 and a pharmaceutically-acceptable excipient.

53. A method of reducing or preventing accumulation of subunit c of mitochondrial ATP synthase in a cell, comprising contacting the cell with a therapeutically-effective amount of the compound or salt of any one of claims 1 to 51 or the pharmaceutical composition of claim 52.

54. The method of claim 53, wherein reducing or preventing accumulation of subunit c of mitochondrial ATP synthase in a cell further comprises treating or preventing a disease or disorder in a subject.

55. A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of the compound or salt of any one of claims 1 to 51 or the pharmaceutical composition of claim 52.Docket No. 31196 / 25102 / PC56. The method of claim 54 or 55, wherein the disease or disorder is associated with impaired autophagy.

57. The method of any one of claims 54 to 56, wherein the disease or disorder is a neurological disease or disorder.

58. The method of any one of claims 54 to 57, wherein the disease or disorder is CLN3 disease, CLN6 disease, a lysosomal storage disorder, Alzheimer's disease, Parkinson's disease, a neurodevelopmental disorder, traumatic brain injury, stroke, Amyotrophic Lateral Sclerosis, Huntington's disease, ischemia, attention deficit disorder, or epilepsy.

59. The method of any one of claims 54 to 58, wherein the disease or disorder is CLN3 disease.

60. The method of any one of claims 54 to 59, further comprising administering to the subject a therapeutical ly-effective amount of one or more additional therapeutic agents.

61. The method of claim 60, wherein the one or more additional therapeutic agents are selected from neurological disease therapeutics, cardiology drugs, antidepressants, antipsychotic drugs, antianxiety drugs, anti-inflammatory drugs, and immune-modulatory drugs.

62. Use of the compound or salt of any one of claims 1 to 51 or the pharmaceutical composition of claim 52 as a medicament for reducing or preventing accumulation of subunit c of mitochondrial ATP synthase in a cell.

63. The use of claim 62, wherein reducing or preventing accumulation of subunit c of mitochondrial ATP synthase in a cell further comprises treating or preventing a disease or disorder in a subject.

64. Use of the compound or salt of any one of claims 1 to 51 or the pharmaceutical composition of claim 52 as a medicament for treating or preventing a disease or disorder in a subject in need thereof.

65. The use of claim 63 or 64, wherein the disease or disorder is associated with impaired autophagy.

66. The use of any one of claims 63 to 65, wherein the disease or disorder is a neurological disease or disorder.

67. The use of any one of claims 63 to 66, wherein the disease or disorder is CLN3 disease, CLN6 disease, a lysosomal storage disorder, Alzheimer's disease, Parkinson's disease, a neurodevelopmental disorder, traumatic brain injury, stroke, Amyotrophic Lateral Sclerosis, Huntington's disease, ischemia, attention deficit disorder, or epilepsy.

68. The use of any one of claims 63 to 67, wherein the disease or disorder is CLN3 disease.

69. The use of any one of claims 63 to 68, further comprising administering to the subject a therapeutical ly-effective amount of one or more additional therapeutic agents.